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ABSTRACT 
 
Rachel R. Markwald (Department of Integrative Physiology) 
The Impact of Melatonin, Melatonin Analogues, Caffeine, and Bright Light on Sleep and 
Thermoregulatory Physiology 
Thesis directed by Associate Professor Kenneth P. Wright, Jr. 
 
The thermoregulatory system is tied to the regulation of sleep and wakefulness. Research 
protocols have examined the unmasked effect of endogenous melatonin on these systems by 
giving exogenous doses under controlled conditions during the daytime, when endogenous levels 
are low.  Study findings have demonstrated that exogenous melatonin improves sleep, increases 
peripheral heat loss, and decreases core body temperature (CBT). These thermoregulatory 
adjustments mimic those that occur around habitual bedtime, when endogenous melatonin levels 
are high. The emergences of artificial light and stimulants i.e., caffeine have impacted the 
behavior and physiology that normally precede sleep. Caffeine may independently impact 
sleep/wakefulness, or in conjunction with the thermoregulatory system.  Bright light during the 
biological night suppresses melatonin and changes the thermoregulatory pattern that precedes 
nocturnal sleep; these changes may ultimately impact the sleep/wakefulness system. To improve 
our understanding of physiological mechanisms promoting and disrupting sleep/wakefulness, it 
is important to examine the connection between melatonin and the sleep/wakefulness and 
thermoregulatory systems, and the impact of environmental and behavioral factors on these 
systems. Therefore, the aims of this dissertation were to: 1) determine the effect of a melatonin 
receptor analogue ramelteon, on daytime sleep and body temperature, and the relationship 
between the two variables; 2) determine the effect of daytime exogenous melatonin on resting 
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energy expenditure, (REE); and 3) determine the individual and compound effects of caffeine 
and bright light on thermoregulatory and sleep physiology at night.   
Consistent with our hypotheses, 1) ramelteon significantly improved daytime sleep, 
lowered CBT, and increased peripheral heat loss 2) exogenous melatonin decreased REE during 
the daytime, and 3) caffeine delayed the nocturnal rise in peripheral heat loss, attenuated the fall 
in CBT, while the combination of caffeine and bright light decreased slow wave sleep and 
increased sleep onset latency.  
These findings suggest that melatonin may play an important role in the regulation of 
sleep/wakefulness as evidenced by the effect of daytime ramelteon administration on sleep and 
thermoregulatory physiology and the effect of daytime exogenous melatonin on REE. Finally, 
caffeine and bright light had a negative impact on nocturnal sleep and these effects may be 
mediated in part by their impact on the thermoregulatory system.  
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SLEEP AND THE THERMOREGULATORY SYSTEM: THE IMPACT OF 
MELATONIN, CAFFEINE, AND BRIGHT LIGHT 
 
 
 
 
 
Rachel R. Markwald 
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Introduction 
Due to many social, economic, and work-related pressures modern society has become an 
environment where most individuals no longer retire at dusk and rise at dawn.  The invention of 
artificial light allowed for the extension of daily activities to occur at all hours of the biological 
night, while the use of central nervous system stimulants such as caffeine has become a common 
strategy to counteract sleepiness. Melatonin is a hormone responsible for mediating many 
physiological, endocrinological, and behavioral processes involved with sleep, and the internal 
circadian clock system (Wright KP Jr. 2007). In particular, it seems to be intimately involved in 
the processes of sleep and thermoregulation.  In humans, melatonin levels are highest at night 
when sleep typically occurs and core body temperature level (CBT) is low.  Additionally, 
exogenous melatonin given during the daytime decreases CBT and increases sleep efficiency in a 
nap opportunity (Cajochen, Krauchi et al. 1996; Cajochen, Krauchi et al. 1997; Hughes and 
Badia 1997).  Further, there is evidence that this is more than just a temporal association between 
sleep and thermoregulation. In fact, they may be causally related to one another, with melatonin 
acting as a link between the two systems (Krauchi, Cajochen et al. 1999; Aoki, Zhao et al. 2008). 
Bright light and caffeine have impacted the behavior and physiology that normally precedes 
sleep during the biological night, thus impacting the relationship between these two processes. 
This chapter addresses what is known about melatonin, melatonergic analogues, caffeine, and 
bright light as they relate to sleep, thermoregulation, and the relationship between these two 
processes.  This review begins with an introduction to the sleep and circadian systems followed 
by a review of research concerning melatonin and melatonergic analogues. Next, the association 
between thermoregulation and sleep will be examined. Finally, this review will conclude with a 
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detailed discussion regarding the impact of two behavioral/environmental factors (caffeine and 
bright light) on sleep and thermoregulation.  
 
Sleep and Circadian Regulation of Sleep/Wakefulness 
Sleep Regulation 
Sleep is under the control of two distinct central nervous system processes. The first 
process is referred to as the homeostatic drive for sleep, or accumulation of sleep need that 
occurs with the accumulation of time awake and which translates to a physiological pressure to 
sleep. This homeostatic sleep drive is thought to promote sleep through inhibition of wakefulness 
promoting brain centers and activation of sleep promoting brain centers. Sleep/wakefulness 
regulation in diurnal animals involves an extensive circuitry of brain regions and cell types 
situated throughout the cortex and brain stem. Several nuclei are involved in the ascending 
arousal system including: the histaminergic tuberomammillary nuclei, serotoninergic dorsal and 
median nuclei and raphe nuclei, noradrenergic locus coeruleus, acetylcholinergic basal forebrain 
and brain stem, and dopaminergic ventral periaqueductal grey matter (Saper, Scammell et al. 
2005). The major monoaminergic systems each send afferent projections to a small cell group 
identified as an important somnogenic region in the brain termed the ventral lateral preoptic area 
(VLPO) of the hypothalamus (Chou, Bjorkum et al. 2002). During wakefulness, these arousal 
cell groups actively inhibit the VLPO. With time awake, however, the homeostatic drive to sleep 
becomes greater and the VLPO is disinhibited. It then inhibits arousal through direct gamma-
Aminobutyric acid  (GABA)ergic and galaninergic projections to each of these nuclei, with 
innervation of the tuberomammillary nuclei, linked to transitions between arousal and sleep (Lu, 
Bjorkum et al. 2002; Ko, Estabrooke et al. 2003).  It has been shown in cats that the nucleotide 
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adenosine (the byproduct of energy metabolism; breakdown of ATP) builds up throughout the 
day in the basal forebrain, and dissipates with sleep (Porkka-Heiskanen, Strecker et al. 1997). 
Further, it has been proposed that adenosine acts on adenosine A1 and A2 receptors located in 
the VLPO and cortex to promote sleep (Saper, Scammell et al. 2005), thus the homeostatic drive 
to sleep might be mediated in part via the gradual accumulation of adenosine acting on A1 and 
A2 receptors.   
 
Circadian Regulation  
The second process that influences sleep/wakefulness is the master circadian clock 
located in the suprachiasmatic nucleus (SCN) of the anterior hypothalamus.  Additionally, there 
are numerous peripheral clocks located in tissue, e.g. liver, vasculature (Ekmekcioglu, 
Haslmayer et al. 2001) that appear to be synchronized to the master circadian clock.  The SCN 
consists of gene regulatory feedback loops which oscillate to a near 24 hr rhythm (Shearman, 
Sriram et al. 2000). This feedback loop is preserved when brain temperature fluctuations occur 
such as those observed with the circadian rhythm of body temperature.  Circadian regulation of 
sleep/wake patterns of diurnal animals involves the extensive circuitry mentioned above with the 
addition of the master circadian clock in the SCN. The SCN has afferent and efferent projections 
to many of the wakefulness promoting nuclei including the neighboring dorsal medial nucleus 
and paraventricular nucleus (Dai, Swaab et al. 1997). When the circadian clock is promoting 
wakefulness, these arousal cell groups actively inhibit the VLPO. As mentioned earlier, the 
VLPO inhibits wake-promoting nuclei, and this is accomplished when the circadian wakefulness 
promoting signal is low and homeostatic drive is high.  
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Circadian regulation of sleep/wakefulness, and its localization to the SCN became 
apparent through several animal studies.  Complete lesions of the SCN appear to abolish sleep 
and temperature circadian rhythms in rodents (Eastman, Mistlberger et al. 1984). Therefore, it is 
thought that the oscillating output of the clock gives time context to most physiological processes 
and behaviors including sleep, and ensures proper entrainment of internal rhythms to the daily 
light–dark cycle.  Thus, the distribution of sleep over the 24-h day is strongly determined by the 
circadian system (Franken and Dijk 2009). 
The average circadian period of the circadian clock in humans is slightly longer on 
average than 24 hrs (Czeisler and Klerman 1999; Wyatt, Ritz-De Cecco et al. 1999; Wright, 
Hughes et al. 2001) and is reset daily by light exposure.  Light modifies the circadian rhythm 
output generated by the SCN, changing neuronal firing rates and synchronizing the internal clock 
to the external environment. Ganglionic photoreceptors in the retina directly transmit light/dark 
signals through the retinohypothalamic tract via glutamatergic input to the SCN and SNS input to 
the pineal gland. Additionally, the SCN receives indirect input from retinal recipient neurons of 
the intergeniculate leaflet via the geniculohypothalamic tract (Morin 1994). A dense serotonergic 
innervation from the median raphe nucleus modulates this photic input via serotonin 1B (5-
HT1B) presynaptic receptors on retinal glutamatergic terminals (Meyer-Bernstein and Morin 
1996), and this function is thought to set the gain of light input to the SCN (Pickard and Rea 
1997). Finally, melatonin production, under control of the circadian clock, provides feedback to 
the SCN through receptor binding to further modify activity of the internal master circadian 
clock.  
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Pineal Gland Regulation of Melatonin 
Melatonin was found to be a hormone responsible for mediating SCN circadian rhythm 
output since removal of its major site of synthesis, the pineal gland, abolished free running 
rhythms in birds housed in darkness. Pineal transplants in these same birds restored rhythmicity 
(Redman, Armstrong et al. 1983). The SCN regulates the near-24-hour circadian rhythm in 
melatonin levels such that under normal conditions, melatonin levels are low during the solar day 
and high during solar darkness.  High circulating levels of melatonin represent the biological 
night in nocturnal and diurnal species (Arendt 1988). It has been estimated in rats that blood flow 
to the pineal gland (4 ml/min/g) is higher than any other endocrine organ excluding the kidney 
(Goldman and Wurtman 1964). Additionally, in most mammals, including rats and humans, the 
pineal gland lacks an endothelial blood-brain barrier (Macchi and Bruce 2004).  Therefore, 
melatonin can directly enter the circulation, as well as enter the cerebral spinal fluid via the 
pineal recess. The most developed pineal afferent is the sympathetic noradrenergic pathway from 
cell bodies in the superior cervical ganglion.  These post-ganglionic neurons receive regulatory 
input from the SCN, which, in turn, receives direct retinal input from retinal ganglion cells as 
described above (Morin 1994). Using radioimmunoassay methods, mean melatonin production 
has been estimated in healthy adults at 28.8 µg/day (Lacoste 1993), with pronounced differences 
between individuals (Bergiannaki, Soldatos et al. 1995).  It is important to note that melatonin 
has been found to display a circadian rhythm when assayed from plasma, urine, and salivary 
samples, thus allowing an accurate method for determining the timing of the internal circadian 
clock.  The circadian melatonin rhythm represents the phase, amplitude, and period of the master 
internal clock (Wright KP Jr. 2007). 
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Melatonin Receptor Physiology 
There are two identified membrane bound melatonin receptors in mammals, MT1 and 
MT2 (previously termed Mel1a and Mel1b when first discovered) (Reppert, Weaver et al. 1994; 
Reppert, Godson et al. 1995).  A third melatonin receptor (Mel1c) has been identified in non-
mammalian vertebrates (von Gall, Stehle et al. 2002).  These receptors belong to the G-protein-
coupled receptor superfamily and contain seven transmembrane domains.  To date, MT1 and 
MT2 receptors have been identified in the mammalian brain centrally: in hypothalamic areas, 
SCN, hippocampus, thalamus, amygdala, cerebellum, ventral tegmental area, nucleus 
accumbens, cerebral cortex, and medial preoptic area (Reppert, Weaver et al. 1988; Weaver, 
Stehle et al. 1993; Morgan, Barrett et al. 1994; Williams, Hannah et al. 1995; Weaver and 
Reppert 1996; Thomas, Purvis et al. 2002) and peripherally including: the retina, the kidney, 
liver,  heart, pancreas, adipocytes, and blood vessels (Brydon, Petit et al. 2001; Ekmekcioglu, 
Haslmayer et al. 2001; Masana, Doolen et al. 2002; Ekmekcioglu, Thalhammer et al. 2003; 
Savaskan, Jockers et al. 2007).  Binding of melatonin to MT1/Mel1a receptors has been reported 
to acutely reduce neuronal firing of SCN neurons.  The reduction in neuronal firing following 
MT1 receptor activation has been hypothesized to be associated with a reduction in the 
wakefulness promoting drive from the SCN.  Therefore, melatonin appears to be involved in 
sleep promotion.  Conversely, MT2/Mel1b have been reported to be primarily involved with the 
phase shifting properties of melatonin (Dubocovich, Yun et al. 1998; Jin, von Gall et al. 2003) 
since MT2 antagonists block the phase shifting effect, and phase shifting capability is unaffected 
in MT1 knockout mice.  Recently, Fisher and colleagues were the first to use a selective subtype 
melatonin ligand (IIK7, a MT2 agonist) demonstrating a sleep promoting action with MT2 
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stimulation in rats, thus challenging the previously held assumption of discrete actions of MT1 
and MT2 receptor mediated effects (Fisher and Sugden 2009).   
 In addition to the membrane-bound melatonin receptors there is cytosolic receptor termed 
MT3 in mammals.  The discovery of this receptor followed the development of specific ligands.  
This melatonin receptor is not G-protein coupled but instead binds to intracellular quinone 
reductase (Nosjean, Ferro et al. 2000).  The MT3 receptor has been hypothesized to be associated 
with antioxidant effects of melatonin (Nosjean, Ferro et al. 2000).   
 
Exogenous Melatonin and Melatonin Analogues 
Exogenous Melatonin 
Exogenous melatonin enters the circulation after absorbance from the small intestine. 
Both endogenous and exogenous melatonin are then transported by the portal circulation to the 
liver, where partial metabolism to 6-hydroxymelatonin occurs, followed by renal excretion. The 
non-metabolized portion of melatonin travels through the systemic circulation to peripheral 
tissues, as well as crossing the blood brain barrier to bind to receptors in the brain. Exogenous 
melatonin has been given in doses equivalent to physiological concentrations, as well as 
pharmacological doses ranging from just above peak endogenous levels to 100X these 
concentrations. Peak levels of exogenous melatonin are observed in the periphery within about 
30-60 minutes post ingestion, with a serum half-life of between 30 and 50 minutes depending on 
the dose. 
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Melatonin Analogues 
Synthetic compounds that closely resemble the chemical structure of melatonin and 
consequently act on MT1 and MT2 receptors have been developed and approved for the 
treatment of insomnia. Due to increased receptor specificity and half-life, melatonin analogues 
such as ramelteon and tasimelteon might be advantageous to melatonin in the treatment of 
certain types of insomnia such as those associated with low melatonin secretion, jet lag, and shift 
work sleep disorder (Pandi-Perumal, Srinivasan et al. 2007). Melatonin analogs are distinct from 
other sleep medications by their mechanism of action. Most over the counter (OTC) sleep aids 
act by antagonizing the effects of the wakefulness promoting actions of histamine on the VLPO. 
Most prescribed sleep medications interact with the GABAergic system, e.g., benzodiazepine 
and non-benzodiazepine hypnotics.  From a public health perspective, melatonin analogues may 
offer a safer alternative to these drugs since OTC and prescribed sleep medications have been 
reported to impair cognition (Srinivasan, Pandi-Perumal et al. 2009) and prescribed medications 
have been reported to be associated with a number of adverse behaviors (Dolder, Lacro et al. 
2002).  
 
Thermoregulation 
Thermoregulation can be thought of as the balance between heat production and heat loss 
at any given moment in time (Van Someren 2006). The range of internal or core body 
temperature (CBT) is tightly regulated by nuclei in the preoptic area of the anterior 
hypothalamus within a narrow range ~1 degree C. These nuclei coordinate appropriate efferent 
responses based on sensory afferent information from core (internal) and peripheral (skin) 
temperature sensitive neurons in order to maintain heat balance (Gilbert, van den Heuvel et al. 
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1999; Harris, Burgess et al. 2001; Charkoudian 2003).  In cold stress conditions, activation of 
sympathetic nerve terminals results in increased binding of norepinephrine on blood vessels 
causing vasoconstriction. Vasoconstriction leads to the narrowing of blood vessel diameter and 
thus a reduction of blood flow to the skin.  This minimizes heat loss to the environment.  
Conversely, during heat stress, the peripheral blood vessels in glabrous and non-glabrous skin 
undergo small increases in vessel diameter (vasodilation) that facilitate heat exchange between 
the body and the environment by redistributing blood flow towards the skin.  This is 
accomplished by two mechanisms: an increase in the cutaneous active vasodilator system and a 
reduction in tonic vasoconstrictor activity (Charkoudian 2003).  
Body temperatures (core and peripheral) display a circadian rhythm that is regulated by 
the master circadian clock located in the SCN.  CBT, as assessed through tympanic and rectal 
thermistors has been shown to have a peak that occurs prior to habitual bedtime, decreases 
through the night, and a nadir that occurs approximately two hours prior to habitual waketime 
(Krauchi, Cajochen et al. 2006).  The circadian rhythm of peripheral temperature measured at 
distal skin sites e.g. the hands and feet, have been shown to be phase advanced with respect to 
CBT (Krauchi, Cajochen et al. 1999; Krauchi, Cajochen et al. 2000).  In accordance with the 
circadian rhythm of peripheral temperature, skin blood flow measured at the finger is 
approximately 4 hrs phase advanced relative to CBT (Smolander, Harma et al. 1993) with a peak 
occurring near the nadir in CBT.  Modulation of blood flow to the distal skin in turn, modulates 
peripheral heat loss.  Thus, it has been shown that the circadian variation in peripheral heat loss 
contributes to ~75% of the oscillation in CBT (Aschoff 1972).  Another method by which 
peripheral heat loss is routinely quantified is by calculation of the distal-to-proximal skin 
temperature gradient (DPG) (Rubinstein and Sessler 1990).  An increase in distal temperature 
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narrows the gradient between the two skin sites, indicating peripheral heat loss at distal sites.  
The DPG is a standard method to measure heat loss since skin blood flow varies greatly 
depending on ambient temperature conditions.  The use of a reference temperature from a 
proximal skin region exposed to the same ambient temperature as the distal skin region provides 
an important internal control standard (Rubinstein and Sessler 1990; Krauchi, Cajochen et al. 
2000).  Further, the sensitivity of this method has been tested in a number of thermoregulatory 
challenges (Frank, Higgins et al. 1997). 
In addition to heat loss, heat production will also affect CBT via changes in metabolic 
rate, (or the energy expended in a given amount of time) (Landsberg, Young et al. 2009).  
Energy expenditure is a result of the caloric cost of cellular, chemical, and mechanical reactions 
that occur in the body.  Since ~70% of metabolism of substrate is lost as heat, this is an effective 
way to increase CBT.  Conversely, decreases in energy expenditure would lower heat production 
and alter CBT (Landsberg, Young et al. 2009).  During cold stress, increases in sympathetic 
nerve activity (SNA) redistribute blood flow away from the periphery, and may also increase 
basal metabolic rate (BMR) through β-adrenergic receptor activation on brown and white 
adipocytes (Shimizu, Nikami et al. 1991).  This is especially true in rodents that possess large 
amounts of brown adipose tissue.  In this way, SNA has been linked to alterations in metabolism 
and heat production.  Additionally, there is a circadian rhythm to energy expenditure and sleep 
has the effect of lowering oxygen consumption as measured by indirect calorimetry when 
compared to a condition of continued wakefulness while lying in bed (Fraser, Trinder et al. 1989; 
Jung, Melanson et al. in press) 
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Thermoregulation and Sleep 
Findings from early studies in humans revealed a close temporal relationship between 
changes in CBT (Czeisler, Weitzman et al. 1980; Zulley, Wever et al. 1981) and peripheral heat 
loss and sleep onset (Haskell, Palca et al. 1981; van den Heuvel, Noone et al. 1998).  Due to the 
time lag needed for heat loss from the periphery to reach the core (called thermal inertia), the 
increase in peripheral heat loss precedes CBT changes by approximately 25 to 100 min (Gilbert, 
van den Heuvel et al. 2004). Peripheral heat loss has been correlated with a faster sleep onset 
latency (SOL) (Krauchi, Cajochen et al. 1997; Krauchi, Cajochen et al. 1999; Krauchi, Cajochen 
et al. 2000). Further, skin warming through the use of a liquid filled, temperature controlled 
whole body suit has been shown to decrease SOL by 27% (Raymann, Swaab et al. 2005).  
Additionally, Raymann and colleagues used this skin thermosuit with healthy sleeping young 
and older subjects and found that proximal warming resulted in deeper sleep and suppressed 
wakefulness, whereas distal skin warming enhanced REM sleep and suppressed light sleep 
(Raymann 2008).  Based on these study findings and work from Krauchi and colleagues 
(Krauchi, Cajochen et al. 1997; Krauchi, Cajochen et al. 2000; Krauchi and Wirz-Justice 2001), 
it is now thought that distal skin temperature (peripheral heat loss) is a better predictor of 
sleepiness and sleep onset than CBT (Krauchi, Cajochen et al. 1999; Krauchi, Cajochen et al. 
2000).  Therefore, it has been proposed that body temperature might act to provide a signal to 
sleep-related neurons in somnogenic brain areas such as the medial preoptic area (McGinty, 
Alam et al. 2001; Szymusiak, Steininger et al. 2001; Gilbert, van den Heuvel et al. 2004) and the 
VLPO (Saper, Scammell et al. 2005).  
  It is possible that initiation of sleep could occur via changes in CBT leading to changed 
spinal cord and brain temperatures (Boulant 1981; Van Someren 2000).  A subpopulation of 
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warm-sensitive POAH neurons spontaneously increases its firing rate at sleep onset and 
experimental warming of the POAH induces a similar increase in this firing rate, and ultimately 
facilitates sleep in animals (McGinty and Szymusiak 1990; Alam, Szymusiak et al. 1995; 
McGinty, Alam et al. 2001).  Selective neuronal activation was observed with c-Fos expression 
during non-rapid eye movement sleep in the medial preoptic nucleus in cats (Torterolo, 
Benedetto et al. 2009).  Additionally, experimental warming of a subset of serotonergic neurons 
in the interfascicular part of the dorsal raphe nucleus (DRI) results in thermoregulatory cooling 
responses such as peripheral heat loss in cats (Cronin and Baker 1977).  Stimulation of the DRI 
alters neural activity in the POAH (Werner and Bienek 1985) and direct projections between the 
two nuclei have been confirmed (Tillet, Batailler et al. 1993).  Additionally, medial preoptic 
inactivation with a GABAA receptor agonist increased c-Fos expression in serotonergic neurons 
in the dorsal raphe nucleus (DRN), suggesting an inhibitory role for the medial preoptic area on 
the wake-promoting activity of the DRN (Kumar, Szymusiak et al. 2008).  Therefore, it is 
possible that a neural network between the POAH and DRN neurons may play a role in the link 
between sleep and temperature regulation.  Sleep, however is not usually attempted during the 
circadian peak of CBT when brain temperature is highest and sleep propensity is at its lowest.  
Therefore, if sleep and thermoregulatory processes are functionally coupled, the peak in CBT 
may trigger a sequence of neural events in preparation for sleep. Alternatively, it is possible that 
a signal may arise elsewhere to turn on the sleep-promoting firing patterns of POAH neurons.   
There is emerging evidence that temperature activated transient receptor potential ion 
channels 3 and 4 (TRPv3 and TRPv4), may play a role in the sensory relay of peripheral 
temperature to the brain (Lowry, Lightman et al. 2009).  These temperature sensitive proteins 
have been located on primary sensory neurons in the skin and respond to increases in 
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temperature within the range of 22 - 42°C (Patapoutian, Peier et al. 2003).  As stated earlier, 
there is a circadian rise in distal skin blood flow (and thus temperature) which precedes CBT by 
~4 hrs (Smolander, Harma et al. 1993).  This increase in distal skin temperature is amplified by 
postural change (Tikuisis and Ducharme 1996; Krauchi, Cajochen et al. 1997), a warm sleep 
environment (Goldsmith and Hampton 1968; Muzet, Libert et al. 1984; Okamoto, Iizuka et al. 
1997), and lights off (Krauchi and Wirz-Justice 2001).  Therefore, it seems plausible that via 
increases in distal skin temperature, skin thermosensory afferents may become activated and 
alter the firing rates of POAH and DRI neurons.  Finally, melatonin via central and peripheral 
effects might act, in part, as a link between the thermoregulatory system and sleep/wakefulness 
regulation.   
 
The Role of Melatonin and Melatonin Analogues in Sleep  
The Effect of Exogenous Melatonin During the Biological Day 
Exogenous melatonin  has been administered during the biological day in physiological 
and pharmacological doses to examine its effect on sleep in humans.  The advantage of this 
model is that acute physiological effects of melatonin can be observed when endogenous 
melatonin levels are low. 
Findings from several studies suggest that melatonin has a soporific effect when the 
circadian rhythm of endogenous melatonin level is low.  Melatonin has been shown to affect 
subjective and objective parameters of sleep and sleepiness.  Dollins et al administered (0.1-
10mg) doses of melatonin at 11:45AM and found that all doses significantly increased sleep 
duration, as well as self-reported sleepiness and fatigue, relative to placebo.  Moreover, all of the 
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doses significantly decreased SOL (Dollins, Zhdanova et al. 1994). Wyatt et al., reported that 
(0.5mg or 5mg) of melatonin given during the daytime increased sleep efficiency in healthy 
adults (Wyatt, Dijk DJ et al. 1999). When three different doses of exogenous melatonin were 
given during the daytime after a seven hour sleep opportunity, all three doses resulted in a 
decrease in SOL, an increase in total sleep time (TST), and a decrease in wake after sleep onset 
(WASO) (Hughes and Badia 1997), additionally, when a 5mg preparation of melatonin was 
given at 1400 to healthy participants there was a 40% decrease in SOL to stage 1 sleep (Reid, 
Van den Heuvel et al. 1996). Further, Gilbert and colleagues compared melatonin (5mg) to the 
commonly prescribed benzodiazepine, temazepam during the daytime and found a similar 
reduction in SOL as compared to placebo (Gilbert, van den Heuvel et al. 1999). This finding also 
occurred when 5mg melatonin was compared to the hypnotic Zopiclone during the daytime 
(Holmes, Gilbert et al. 2002). The repeated finding that exogenous melatonin improves sleep 
when endogenous levels are low makes it a prime candidate for the treatment of circadian 
rhythm sleep disorders such as jet lag. 
 
The Effect of Exogenous Melatonin During the Biological Night 
There has been extensive research in humans on the use of exogenous melatonin during 
the biological night with varying results on sleep. Early studies investigated the effects of high 
doses of melatonin administered intravenously. Cramer and colleagues reported sleep inducing 
effects of 50 mg iv melatonin (Cramer, Rudolph et al. 1974), and Anton-Tay et al, reported that 
melatonin administration of between 0.25-1.25 mg/kg reduced sleep latency (Anton-Tay, Diaz et 
al. 1971).  Additionally, melatonin (0.1-0.3mg) decreased SOL and latency to stage 2 sleep when 
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compared to placebo, with no significant effect on other sleep parameters (Zhdanova, Wurtman 
et al. 1996). In summary, most findings from nighttime melatonin administration in healthy 
sleepers have only observed significant decreases in SOL.  
 
Melatonin Analogues and Sleep 
There are several melatonin analogues currently on the market or undergoing clinical 
trials. It should be acknowledged that most studies were designed to examine the effects of using 
a melatonergic analogue on circadian phase shifting. Only the studies that pertain to the acute, 
soporific effects of melatonin analogues will be discussed in this section. 
Ramelteon, (S )-N-[2-(1,6,7,8-tetrahyrdo-2H-indeno - [5,4-b]furan-8-
yl)ethyl]propionamide (TAK-375), is a high affinity selective MT1/MT2 receptor agonist that 
shows approximately four times greater potency at the MT1 receptor and 17 times greater 
potency at the MT2 receptor compared to melatonin, with very low affinity for binding to the 
MT3 (non membrane-bound) receptor or other neurotransmitter receptor systems (Kato, Hirai et 
al. 2005).  It has been shown that ramelteon, unlike other hypnotics, acts preferentially on the 
MT1 and MT2 receptors of the SCN (Hirai, Kato et al. 2003).   
Two randomized, placebo controlled single dose trials were conducted to determine the 
efficacy of ramelteon in a transient model of insomnia in which healthy volunteers were required 
to sleep in a novel environment. In the first study, 375 participants received either placebo or 
ramelteon 16 or 64 mg administered 30 minutes prior to habitual bedtime. Ramelteon improved 
latency to persistent sleep by approximately 10 minutes, and total sleep time increased by 
roughly 12 minutes, largely due to shortened sleep latencies (Roth, Stubbs et al. 2005).  Using a 
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similar methodology, 289 adults were randomized to placebo or ramelteon 8 or 16 mg.  
Compared to placebo, ramelteon 8 mg decreased sleep latency by 7.5 minutes (Zammit, 
Schwartz et al. 2009). The effects of ramelteon on a daytime sleep paradigm have not been 
assessed. 
Tasimelteon (VEC-162, previously known as BMS-214778) ((1R-trans)-N-[[2-(2,3-
dihydro-4-benzofuranyl)cyclopropyl] methyl] propanamide) is a melatonin receptor agonist with 
high affinity for MT1 and MT2 receptors (Rajaratnam, Polymeropoulos et al. 2009). Two recent 
randomized controlled trials (phase II and III) demonstrated that tasimelteon dose-dependently 
improves the initiation and maintenance of sleep after a 5-hour advance of the sleep-wake and 
light-dark cycle, and that these effects occurred simultaneously with a phase advance of the 
plasma melatonin rhythm (Rajaratnam, Polymeropoulos et al. 2009). Since tasimelteon improved 
sleep at a scheduled time when melatonin levels are low the authors suggest that the compound 
has potential for treatment of circadian rhythm sleep disorders.   
 
The Role of Melatonin in Thermoregulation 
Melatonin and Thermoregulation during the Biological Day 
Administration of exogenous melatonin during the biological daytime, when endogenous 
melatonin levels are low, has been shown to reduce CBT (Dawson, Gibbon et al. 1996; Reid, 
Van den Heuvel et al. 1996; Hughes and Badia 1997; Satoh and Mishima 2001), and increase 
peripheral heat loss (Krauchi, Cajochen et al. 2000; Aoki, Stephens et al. 2003; Aoki, Stephens et 
al. 2006; Krauchi, Cajochen et al. 2006). This melatonin-induced increase in peripheral heat loss 
is reported to be correlated with a decrease in SOL (Krauchi, Cajochen et al. 1999; Krauchi, 
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Cajochen et al. 2000; Lack and Gradisar 2002). Heat loss following exogenous melatonin 
administration has been primarily determined by measuring skin temperature levels, at the hands 
and feet (Aoki, Yokoi et al. 2005; Krauchi, Cajochen et al. 2006; Aoki, Zhao et al. 2008), and by 
calculating the distal-proximal gradient (DPG) in skin temperature as described earlier (Krauchi, 
Cajochen et al. 2000). This hypothermic effect observed during the daytime mimics the natural 
progression of thermoregulatory events that occur at nighttime when endogenous melatonin 
levels begin to rise. Increases in peripheral heat loss are highly correlated with increases in blood 
flow to the skin (Rubinstein and Sessler 1990). Aoki and colleagues have used the laser Doppler 
flowmetry technique to assess the thermoregulatory effects of daytime melatonin administration 
by measuring changes in skin blood flow. Using a cold thermic challenge test to reduce CBT, it 
was shown that skin blood flow was higher in the melatonin (3mg) condition than placebo 
condition. Melatonin-induced sleepiness in participants occurred in parallel with a reduction in 
the threshold for vasoconstrictor activity. This change in thermoregulatory set-point might 
indicate that melatonin acts as a circadian modulator of the thermoregulatory set-point (Aoki, 
Zhao et al. 2008). Additionally, exogenous melatonin caused a shift to lower temperatures in the 
blood flow response to internal temperature during whole body heating (Aoki, Stephens et al. 
2006) and this was most likely accomplished through the cutaneous active vasodilator system 
(JM 1996). Thus, neural control of both the cutaneous vasoconstrictor and active vasodilator 
systems are affected by exogenous melatonin administration, suggesting that secretion of 
melatonin at night might play an important role in nocturnal thermoregulation via the 
sympathetic nervous system.  
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Melatonin and Thermoregulation during the Biological Night 
 The skin blood flow promoting property of melatonin may account for ~40% of the 
amplitude of the circadian rhythm in CBT due to heat loss under resting conditions (Cagnacci, 
Elliott et al. 1992). As mentioned earlier sleep is usually attempted ~2 hrs after endogenous 
melatonin levels begin to rise. It is possible that endogenous melatonin may affect 
sleep/wakefulness regulation through potential central and peripheral effects on blood flow and 
skin temperature.  Exogenous melatonin administration to healthy sleepers when endogenous 
levels are already high has not been reported to have any further effect on thermoregulatory 
variables. 
  
Energy Expenditure 
Melatonin has been shown to play a role in energy expenditure and body mass regulation 
in hibernating mammals (Bartness, Demas et al. 2002).  In nocturnal animals, melatonin has been 
proposed to increase the thermogenic capacity of the animal by increasing sympathetic activity 
to white and brown adipose tissue. Additionally, there is correlational evidence from studies of 
rats that daily melatonin administration suppressed the age-related gain in visceral fat 
(Rasmussen, Boldt et al. 1999; Prunet-Marcassus, Desbazeille et al. 2003) and prevented the 
increase in body fat normally observed in ovariectomized rats (Ladizesky, Boggio et al. 2003). A 
reduction in CBT (0.3°C) has also been shown with a MT2 melatonin analogue in rats (Fisher 
and Sugden 2009). As stated earlier, melatonin has an acute hypothermic effect on CBT in 
humans that is partly mediated through changes in peripheral heat loss. It has long been 
recognized that the drop in core temperature that occurs during sleep is mainly the result of an 
increase in heat dissipation, and to a lesser extent the result of a decrease in metabolic heat 
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production (Van Someren 2006). In humans, it remains to be determined if melatonin or a 
melatonin analogue can acutely modulate energy expenditure and thus contribute to the observed 
thermoregulatory effects of melatonin. This question will be addressed in chapter 3 of this 
dissertation. 
 
Melatonin analogues and thermoregulation 
Given the extensive evidence that melatonin alters thermoregulatory physiology through 
its hypothermic effect on CBT, and increase in heat loss, it seems logical that a melatonin 
analogue such as ramelteon might have the same effect. Additionally, given the temporal 
association (Czeisler, Weitzman et al. 1980; Zulley, Wever et al. 1981) and recent evidence for a 
functional, mechanistic link between body temperature and sleep (Krauchi, Cajochen et al. 2000; 
Gilbert, van den Heuvel et al. 2004; Krauchi, Cajochen et al. 2006; Aoki, Zhao et al. 2008) it will 
be important to assess temperature changes with melatonin analogues and will be addressed in 
chapter 2 of this dissertation.  
 
The Effect of Caffeine on Sleep and Wakefulness 
Caffeine is a methylxanthine and an adenosine antagonist that is widely used to promote 
wakefulness. There have been three identified mechanisms of action by caffeine: intracellular 
mobilization of calcium, inhibition of phosphodiesterases, and antagonism at the level of 
adenosine receptors (Nehlig, Daval et al. 1992). It is the latter of these three mechanisms that is 
most likely to mediate caffeine’s effects in the central nervous system (Nehlig, Daval et al. 
1992). Adenosine is a byproduct of cellular metabolism that binds to adenosine A1 and A2A 
receptors throughout the central nervous system (Dunwiddie 1985), and in the periphery 
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(Schindler, Karcz-Kubicha et al. 2005). In the brain, adenosine accumulates with time spent 
awake from the previous sleep episode and dissipates during sleep. Consequently, it is 
considered a marker of sleep homeostatic pressure and regarded as a sleep promoting substance. 
As adenosine accumulates with time awake it may exert its sleep promoting effect via binding to 
adenosine receptors in the VLPO (Saper, Scammell et al. 2005), other sleep/wakefulness 
associated nuclei, i.e. activation of noradrenaline neurons (Nehlig, Daval et al. 1992), reduction 
in serotonin availability at postsynaptic receptor sites (Hirsh 1984)), or through its effect on 
pineal melatonin levels (Sarda, Cespuglio et al. 1989). There is evidence that adenosine binds to 
adenosine receptors on the pineal gland (Sarda, Cespuglio et al. 1989), and increases melatonin 
levels in a dose dependent manner (Gharib, Reynaud et al. 1989). Further, caffeine blocked the 
increase in pineal melatonin after the adenosine agonist 5'-N-ethylcarboxamidoadenosin was 
given (Babey, Palmour et al. 1994). Specifically, there is some evidence that caffeine’s arousal 
effect is mediated via the adenosine A2A receptor since A2A receptor knockout mice do not show 
a strong sleep rebound after sleep deprivation and caffeine does not induce wakefulness in these 
mice (Huang Zhi-Li 2005). It has been suggested that the effect of caffeine on sleep/wakefulness 
may also be mediated, in part, by caffeine’s action on melatonin levels during the biological 
night, and in turn, modulation of melatonin’s effects on temperature (Wright KP 1997). This has 
not yet been studied. Chapter four of this dissertation will address this question.  
 
The Effect of Caffeine on Thermoregulation 
Previous studies have reported that caffeine attenuates the nocturnal decrease in CBT 
when compared to dim light exposure in humans, (Wright, Badia et al. 1997; Wright, Myers et 
al. 2000), and increases brain temperature in rats (Pechlivanova, Tchekalarova et al.) Further, 
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caffeine in doses ranging from 2 to 8 mg/kg of body weight has been shown to increase resting 
metabolic rate (RMR) in humans (Acheson, Zahorska-Markiewicz et al. 1980; Arciero, Gardner 
et al. 1995; Arciero, Bougopoulos et al. 2000; Acheson, Gremaud et al. 2004). Astrup and 
colleagues found a dose response relationship for RMR to 100, 200, and 400 mg caffeine that 
resulted in 9.2 ± 5.7, 7.2 ± 6.0, and 32.4 ± 8.2 kcal/hour above the placebo responses, 
respectively (Astrup, Toubro et al. 1990). This increase in RMR, if uncompensated for, would 
increase CBT since ~70% of energy is lost as heat during metabolic processes (Cagnacci, Elliott 
et al. 1992). There is minimal evidence as to caffeine’s effect on skin temperatures in a 
controlled laboratory setting. Past studies have shown a decrease in finger temperature (France 
and Ditto 1992), while others have shown no change in forearm blood flow (Umemura, Ueda et 
al. 2006). The effect of caffeine on the DPG has never been looked at in humans and is addressed 
in chapter four of this dissertation.  
  
Bright Light and Thermoregulation 
 It was first discovered 30 years ago that bright light exerts a strong influence on the 
circadian system when Lewy and colleagues noticed that after exposure to bright light, melatonin 
levels in the blood were suppressed (Lewy et al. 1980). It was further discovered the amount of 
suppression is intensity dependent (McIntyre et al. 1989), and response time is rapid (Lewy et al 
1984). Additionally, bright light given during the biological night prevents the normal decline in 
the CBT rhythm compared to a dim light placebo condition (Badia, Myers et al. 1991; Dijk, 
Cajochen et al. 1991; Wright, Badia et al. 1997; Burgess, Sletten et al. 2001; Cajochen, Munch et 
al. 2005). Further, bright light of two different spectral frequencies (460 nm and 550 nm) 
decreased the DPG to the same extent when light exposure occurred in the late evening 
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(Cajochen, Munch et al. 2005). The effect of bright light on thermoregulatory physiology is 
mediated through the SCN. This may be a direct effect as findings from animal studies have 
identified neural projections from the SCN to the subparaventricular hypothalamic nucleus (SPZ) 
and efferents from the SPZ to temperature regulating neurons in the POAH (Saper, Scammell et 
al. 2005). It may also be a reflection of endogenous melatonin suppression, thus removing the 
ability of the neurohormone to bind to its receptors in the brain (i.e. SCN and POAH), and exert 
thermoregulatory effects.  The effect of bright light in combination with caffeine has never been 
examined for skin temperatures (i.e., the DPG) in humans and will be addressed in chapter four 
of this dissertation. 
 
Summary 
This literature review has highlighted several research studies in animals and humans 
aimed at understanding the relationship between the sleep and thermoregulatory processes.  In 
general, there is evidence that endogenous melatonin plays a role in the integration of these two 
systems. Further that caffeine and bright light (two common behavioral and environmental 
factors) impact each system directly, or via their impact on endogenous melatonin. The complex 
relationships that exist between sleep, thermoregulatory, and melatonin physiology make it 
difficult to elucidate which factors preceding sleep at night are causally related to one another. 
Therefore, several questions remain pertaining to the nature of these relationships and if 
answered, may aid in the development of treatment interventions for the diverse number of sleep 
problems that affect the population. For example, it is has been suggested that it is the peripheral 
heat loss (change in DPG) that occurs during the nocturnal increase in melatonin levels that is 
most predictive of SOL. This may be of relevance, but SOL may also be impacted by a potential 
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role for melatonin on metabolic physiology, a question that has not yet been examined in 
humans.  Further, it is necessary to recognize the potential impact of caffeine consumption and 
bright light at night on the thermoregulatory variables (i.e. DPG) that have been shown to be 
predictive of SOL. Finally, with the development of melatonin analogues, coupled with the 
increased number of individuals attempting to sleep during the biological day (i.e. night shift 
workers), it will be important to understand if these medications are effective at promoting sleep 
during the biological day because they mimic the nocturnal thermoregulatory pattern that occurs 
when endogenous melatonin levels are high.  
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Dissertation Aims 
The aim of this dissertorial work was to further explore the relationship between the sleep 
and thermoregulatory processes. The following questions were addressed: 1) Does a melatonin 
analogue, ramelteon, improve daytime sleep in part, due to thermoregulatory effects on DPG and 
CBT similar to what is observed during the biological night? 2) Is a daytime dose of exogenous 
melatonin capable of reducing resting energy expenditure thereby affecting heat production and 
CBT? 3) Does a commonly consumed dose of caffeine in the early evening affect the DPG, as 
well as the pattern of other thermoregulatory variables? Is this dose of caffeine disruptive to 
sleep scheduled six hours later and is it associated with changes in the DPG. Further, is there a 
compound effect of caffeine and bright light on the DPG and sleep quality during the biological 
night? Specifically, the following hypotheses were tested: 1) Ramelteon (a melatonin analogue) 
would reduce core temperature, increase the DPG, as well as shorten SOL, reduce WASO and 
increase TST during a daytime sleep opportunity 2) Daytime exogenous melatonin 
administration (5 mg) would reduce resting metabolic rate and calculated energy expenditure 
compared to placebo 3) caffeine would act individually and in combination with bright light to 
attenuate the circadian fall in CBT, attenuate the circadian rise in the DPG during the time of 
habitual bedtime, as well as increase SOL and decrease slow wave sleep during a nighttime sleep 
opportunity. 
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Abstract 
 
Study Objectives: A reduction in core temperature and an increase in the distal-proximal skin 
gradient (DPG) are reported to be associated with shorter sleep onset latencies (SOL) and better 
sleep quality.  Ramelteon is a melatonin MT-1/MT-2 agonist approved for the treatment of 
insomnia.  At night, ramelteon has been reported to shorten SOL.  In the present study we tested 
the hypothesis that ramelteon would reduce core temperature, increase the DPG, as well as 
shorten SOL, reduce wakefulness after sleep onset (WASO) and increase total sleep time (TST) 
during a daytime sleep opportunity.   
Design: Randomized, double-blind, placebo-controlled, cross-over design.  8 mg ramelteon or 
placebo was administered 2 h prior to a 4 h daytime sleep opportunity.  
Setting:  Sleep and chronobiology laboratory. 
Participants:  Fourteen healthy adults (5 females), aged (23.2 ± 4.2 yrs).  
Results:  Primary outcome measures included core body temperature, the DPG and sleep 
physiology [minutes of TST, WASO and SOL]. We also assessed as secondary outcomes, 
proximal and distal skin temperatures, sleep staging and subjective TST.  Repeated measures 
ANOVA revealed ramelteon significantly reduced core temperature and increased the DPG (both 
P<0.05).  Furthermore, ramelteon reduced WASO and increased TST, stages 1, & 2 sleep (all 
P<0.05).  The change in the DPG was negatively correlated with SOL in the ramelteon 
condition.   
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Conclusions: Ramelteon improved daytime sleep, perhaps mechanistically in part by reducing 
core temperature and modulating skin temperature.  These findings suggest that ramelteon may 
have promise for the treatment of insomnia associated with circadian misalignment due to 
circadian sleep disorders.
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Introduction 
 Insomnia is a common symptom of circadian sleep disorders (Sack, Auckley et al. 2007). 
Circadian sleep disorders are a special class of sleep disorders that are often associated with 
misalignment between internal biological time and the desired or imposed sleep-wakefulness 
schedule (Sack, Hughes et al. 1997; Sack, Auckley et al. 2007; Sack, Auckley et al. 2007). The 
resulting circadian misalignment leads to sleep occurring at an internal biological time when the 
circadian clock is promoting wakefulness.  Humans usually initiate sleep on the downward slope 
of the circadian body temperature rhythm (Czeisler, Weitzman et al. 1980), when the rate of 
change of core temperature and peripheral heat loss are maximal and when endogenous levels of 
melatonin begin to rise (Zulley, Wever et al. 1981; Campbell and Broughton 1994). A close 
temporal relationship between sleep and core body temperature (CBT) has been found, such that 
sleep is optimal during the biological night when CBT is low and also when endogenous 
melatonin levels are high (Czeisler, Weitzman et al. 1980; Zulley, Wever et al. 1981; Dijk and 
von Schantz 2005).  
Administration of exogenous melatonin during the biological day, when endogenous 
melatonin levels are low, has been shown to reduce CBT (Dawson, Gibbon et al. 1996; Reid, 
Van den Heuvel et al. 1996; Hughes and Badia 1997; Satoh and Mishima 2001), increase 
peripheral heat loss (Krauchi, Cajochen et al. 1997; Krauchi, Pache et al. 2002; Aoki, Stephens et 
al. 2006; Aoki, Zhao et al. 2008), and improve sleep (Wright KP Jr. 2007). The increase in 
peripheral heat loss is reported to be negatively correlated with sleep onset latency (SOL) 
(Krauchi, Cajochen et al. 1999; Krauchi, Cajochen et al. 2000; Lack and Gradisar 2002).  Heat 
loss following exogenous melatonin administration has been primarily determined by measuring 
skin temperature levels at the hands and feet (Aoki, Yokoi et al. 2005; Krauchi, Cajochen et al. 
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2006; Aoki, Zhao et al. 2008) and by calculating the distal-proximal gradient (DPG) in skin 
temperature (Krauchi, Cajochen et al. 2000).  The DPG was first developed by subtracting 
fingertip temperature from a site on the forearm (Rubinstein and Sessler 1990), and has been 
modified by others (Krauchi, Cajochen et al. 2000; van der Helm-van Mil, van Someren et al. 
2003) to be calculated as the difference in distal skin temperature sites on the hands and feet 
minus skin temperature levels at proximal sites such as the chest. The sensitivity of the DPG 
method has been tested in a number of thermoregulatory challenges (Frank, Higgins et al. 1997).  
Heat loss has also been assessed through thermoimaging of the palmar and dorsal surfaces of the 
hand and fingers (Krauchi, Cajochen et al. 2006) and measurement of cutaneous blood flow 
(Aoki, Stephens et al. 2003; Aoki, Stephens et al. 2006; Aoki, Zhao et al. 2008). During the 
biological night, exogenous melatonin administration decreases SOL with little effect on sleep 
architecture (Zhdanova, Wurtman et al. 1996); whereas during the biological day, exogenous 
melatonin administration decreases SOL (Dollins, Zhdanova et al. 1994; Reid, Van den Heuvel 
et al. 1996; Gilbert, van den Heuvel et al. 1999; Holmes, Gilbert et al. 2002) and wakefulness 
after sleep onset (WASO) (Hughes and Badia 1997) and increases total sleep time (TST) 
(Dollins, Zhdanova et al. 1994; Hughes and Badia 1997; Wyatt, Dijk et al. 2006). 
Ramelteon is a sleep promoting therapeutic approved for the treatment of insomnia that 
acts specifically on melatonin MT-1 and MT-2 receptors with a greater affinity and a longer half-
life than melatonin at these receptors (Pandi-Perumal, Srinivasan et al. 2007). Additionally, 
ramelteon has no affinity for the cytosolic MT-3 receptor (Pandi-Perumal, Srinivasan et al. 
2007).  At night, ramelteon has been reported to decrease SOL and thereby increase TST in 
healthy sleepers on the first night sleeping in a novel environment (Zammit, Schwartz et al. 
2009).  Ramelteon was also reported to decrease SOL in older adults with chronic insomnia over 
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five weeks of treatment (Roth, Seiden et al. 2006). Further, a 6 month study showed that nightly 
ramelteon administration reduced both electroencephalograph (EEG) determined latency to 
persistent sleep as well as subjective SOL in adults with chronic primary insomnia (Mayer, 
Wang-Weigand et al. 2009). 
The influence of ramelteon on thermoregulatory physiology and daytime sleep in humans 
is unknown.  If improvements in daytime sleep following ramelteon are associated with 
decreases in CBT and increases in peripheral heat loss, such findings may provide information 
regarding possible physiological mechanisms by which ramelteon improves sleep during the 
biological day.  Furthermore, showing the efficacy of ramelteon for improving sleep during the 
biological day would provide support for testing the application of ramelteon in the treatment of 
insomnia due to circadian sleep disorders (e.g., jet lag, shift work, delayed sleep phase).  
Therefore, we tested the hypothesis that ramelteon (8mg) would reduce CBT and increase the 
DPG under controlled bed rest conditions, as well as decrease SOL and WASO and increase TST 
in a daytime sleep opportunity.  We also hypothesized that a greater change in DPG would be 
associated with a shorter SOL. 
 
Methods 
Subjects 
Fourteen healthy adults (5 females), aged (23.2 ± 4.2 yrs; mean ± SD), body-mass index 
(22.5 ± 2.7 kg/m2) participated.  Women were studied during the follicular phase of their 
menstrual cycle to control for effects of decreased responsiveness to daytime melatonin 
administration during the luteal phase (Cagnacci, Soldani et al. 1996).  Participants underwent a 
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medical evaluation at the Clinical and Translational Research Center (CTRC) at the University 
of Colorado – Boulder.  Participants were admitted into the study if they were free of any 
medical conditions as determined by medical and psychiatric history, physical exam, blood 
chemistries, 12-lead clinical electrocardiogram, and urine toxicology for drug use.  Exclusion 
criteria were: current smoker, not lived at Denver/Boulder altitude (1600 m) for at least one year, 
any medical, psychiatric, or sleep disorder, habitual sleep duration <6 or >9 h, and taking any 
medication.  Study procedures were approved by the University of Colorado - Boulder IRB and 
the Scientific Advisory and Review Committee of the CTRC.  Participants gave written-
informed consent, and all procedures were performed according to the Declaration of Helsinki.  
Study Design 
A randomized, within-subject, crossover, placebo-controlled research design was used in 
which participants spent two separate days in the laboratory separated by one week.  Both visits 
occurred on the same day of the week.  Each laboratory visit was preceded by a one week 
consistent sleep-wakefulness schedule verified by call-ins to a time stamped recorder, actigraphy 
recordings (Actiwatch-L, Mini Mitter Respironics, Bend, OR) and sleep logs.  Participants 
refrained from caffeine, nicotine, and over-the-counter drugs.  Urine toxicology and breath 
alcohol testing (Lifeloc Technologies Model FC10, Wheat Ridge, CO) verified participants were 
free of drugs each visit. 
Ramelteon and placebo administration were double-blind.  Computerized implementation 
of treatment allocation was performed by the CTRC pharmacist who provided pills identical in 
appearance in numbered containers.  Participants received either ramelteon or rice-powder filled 
placebo pills on the first visit with the alternate condition administered on the second visit.  The 
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allocation sequence was concealed until interventions were assigned and data prepared for 
statistical analysis. 
 
Experimental Procedures 
Participants were admitted ~1 h 50 min after their habitual wake time to control for 
circadian phase within individuals between visits.  Shortly after arrival to the lab, participants 
were prepared for polysomnography (PSG) and temperature physiology recordings.  Participants 
were studied using a modified constant routine protocol in which they remained awake, seated in 
a semi-recumbent position in a hospital bed with the head raised at ~35 degrees.  Participants 
were studied in an environment free of time cues in dim light (< 8 lux maximum), sound 
attenuated and temperature controlled rooms.  One exception to the latter was that participants 
were informed in the consent form that they would be asked to sit in bed awake for ~4 h out of 
each ~10 h study visit.  Throughout the protocol participants wore a light tee shirt and a blanket 
covered them up to their waistline to provide for similar microclimate conditions at the skin 
temperature recording sites.  A prepared lunch was given of the exact same quantity and dietary 
composition for both visits to control for the thermoregulatory effects of digestion and 
absorption.  The lunch was served at the same time each visit and occurred 1 h and 45 min prior 
to pill administration.  The timing of the meal was designed so that ramelteon would be rapidly 
absorbed and to reduce effects of hunger on the subsequent sleep episode.  Core and skin 
temperature physiology and daytime sleep measurements were performed during the biological 
day on the circadian rise of the CBT rhythm.  Core and skin temperature recordings began ~2.5 h 
following habitual waketime.  Ramelteon or placebo was administered 2 h after sitting in bed.  
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At 2 h after drug administration, the bed was lowered to the supine position and the lights were 
turned off for a 4 h sleep opportunity (Fig 1).  If participants awoke before the end of the sleep 
opportunity they were instructed to continue lying in bed and try to sleep. 
 
Temperature Recording 
Core temperature was measured via an ingested temperature pill that transmitted internal 
temperature by radio frequency to an external unit placed around the participant’s waist (Vital 
Sense, Mini Mitter Respironics, Bend, OR).  Proximal and distal skin temperatures were 
measured via thermopatches placed inferior to the left clavicle, at the location of the subclavian 
vein (Tsub), and the left dorsal foot (Tft) respectively.  The DPG was calculated as the difference 
between the (Tft) and the (Tsub) thermopatches.  Core and skin body temperatures were analyzed 
for 2.67h prior to the PSG recorded sleep opportunity. 
 
Polysomography Recording  
Sleep recordings were obtained with Siesta digital sleep recorders (Compumedics USA 
Ltd, Charlotte, NC) using monopolar EEGs referenced to contra-lateral mastoids according to the 
International 10-20 system (C3-A2, C4-A1, O1-A2 and F3-A2), right and left electrooculograms 
(EOG), chin electromyogram (EMG), and electrocardiogram (ECG).  Impedances were below 5 
kohms. Data were stored and sampled at a rate of 256 samples per second per channel with a 12-
bit A-D board.  High and low pass digital filters for EEG and EOG were set at 0.10 and 30 Hz, 
respectively.  High and low pass digital filters for EMG were set at 10 and 100 Hz, respectively.   
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Figure 1:  Protocol Timeline 
Protocol events were scheduled according to habitual bed and wake times.  The example depicts 
a protocol for a participant with a habitual wake time of 0700 h. Participants were admitted to the 
laboratory ~1 h 50 min after their scheduled wake time.  Pill administration is denoted by the 
arrow and occurred 2 h after the admit and 2 h prior to the 4 h sleep opportunity.  
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Sleep was scored according to standard guidelines from brain region C3-A2 (Rechtschaffen A. 
1968).  SOL was defined as the time from lights out to the onset of three continuous epochs of 
EEG defined sleep.  Subjective TST was assessed immediately after each sleep opportunity.  One 
participant did not provide a subjective assessment of TST and was therefore not included in that 
analysis.  
 
Data Analysis  
Actigraphic analysis of sleep the week prior to each visit verified a similar amount of 
sleep between conditions with an average difference in TST of 0.01 h (± 0.30 SD). 
The primary outcome variables for body temperature were CBT and the DPG. Post hoc 
analyses were also performed on Tsub and Tft.  Data for each body temperature measure were 
averaged into 10-minute bins.  Differences from pill administration were calculated for DPG 
measures to control for between subject differences in the baseline distal skin temperature level.  
Data from two individuals were not used for the CBT analysis due to temperature pill 
malfunction.   There was missing data for one individual for Tsub, and four individuals for Tft due 
to technical difficulties.  The four individuals who did not have Tft data were consequently not 
included in the DPG analysis.  The allocation sequence resulted in a balanced design despite 
these missing data.  The primary outcome variables for sleep were TST, WASO and SOL.  
The effects of ramelteon versus placebo on each of the above variables were compared 
using repeated-measures analyses of variance (ANOVA) with Hunyh Feldt degree of freedom 
correction factors to address heterogeneity of variance.  Planned comparisons were conducted 
between each condition for every time bin for temperature and summary measures for sleep 
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episode.  Multiple comparisons were examined with Fishers least significant difference tests 
combined with a modified Bonferroni correction to reduce type I error.  Data are expressed as 
mean ± standard error of the mean (SEM).  A priori Pearson’s correlation coefficients were 
computed between DPG and SOL measures because findings from prior studies indicated 
relationships among these measures.(Krauchi, Cajochen et al. 2000)  In addition, post hoc 
Pearson’s correlation coefficients were computed for the change from baseline in CBT, Tsub, Tft 
or DPG and sleep measures.  Baseline temperature level was defined as the 40 minutes prior to 
pill administration and was compared to the average change in temperature for the 110 minutes 
following pill administration for the correlation analyses.  
 
Results 
Body Temperature 
Ramelteon (8 mg) significantly attenuated the circadian rise in CBT (Fig 2A) and significantly 
increased the DPG (Fig 2B) compared to placebo.  There was a significant main effect of time 
and interaction of drug by time for CBT (Table 1).  Additionally, there was a significant main 
effect of time for the DPG.  Planned comparisons revealed a significant difference in the 
ramelteon condition for the DPG beginning 50 min prior to the sleep opportunity.  There was a 
significant interaction of condition by time (Table 1) for Tsub with significant differences 
between conditions at 50 min and 110 min after drug intake.  There was a higher proximal 
temperature at 50 min and a lower proximal temperature at 110 min in the ramelteon condition 
(Figure 2C).  We found a significant main effect of time for Tft (Figure 2D).  
 
48 
 
Table 1: ANOVA Results for thermoregulatory variables 
Measure Drug Time DxT 
    
CBT 
F(1,11)=4.12, 
p=0.067 
F(10,110)=2.88,  
p=0.003* 
F(10,110)=3.94, 
p=0.00013* 
DPG 
F(1,9)=.89, 
p=0.370 
F(10,90)=11.09, 
p=.00000* 
F(10,90)=1.49, p=0.154 
Tsub 
F(1,12)=.078 
P=0.79 
F(10,120)=1.04 
P=0.41 
F(10,120)=3.09 
P=.002* 
Tft 
F(1,9)=.28 
P=0.61 
F(10,90)=10.84 
P=0.00000* 
 
F(10,90)=.89 
P=0.55 
 
*denotes a significant value. 
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Figure 2:  Thermoregulatory effects of ramelteon on core body temperature, the DPG, 
proximal and distal skin temperature sites.    
Values expressed as means ± SEM.  The open circles represent the ramelteon condition and 
closed circles represent the placebo condition. The 0 point denotes time that ramelteon or 
placebo were administered. (A) The melatonin agonist, ramelteon, significantly reduced core 
temperature by attenuating the normal daytime circadian rise as seen in placebo. (B) The DPG 
was increased after ramelteon ingestion relative to placebo. (C) Proximal skin temperature 
measured at the subclavian vein (Tsub ) (D) Distal skin temperature measured at the dorsal foot 
(Tft). 
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Sleep Physiology 
Ramelteon significantly reduced % wakefulness and WASO and significantly increased 
PSG recorded and subjective TST (Table 2).  Increased sleep duration was primarily due to 
significant increases in the percentage of stages 1 and 2 sleep, with non-significant changes in 
slow wave sleep (SWS), rapid eye movement sleep (REM) and SOL (Table 2).  
 
Correlations Between Temperature and Sleep Physiology 
In the placebo condition, there were no significant correlations for the DPG (Figure 3A, 
p=0.28), CBT, Tsub, Tft temperatures with any sleep measure. Whereas, in the ramelteon 
condition there were significant negative correlations for the DPG with SOL (Figure 3B, 
p=0.013) and with percent of stage 1 sleep (r =.-73, p =.02).  Similarly, Tft was negatively 
correlated with SOL (r = .68, p = .03) and with percent of stage 1 sleep (r = -.71,p = .02). 
Additionally, Tft was positively correlated with percent of stage 3/4 sleep (r = .69, p = .03).  
There were no significant correlations with CBT or Tsub and any sleep measure in the ramelteon 
condition.  It appears in Figure 3A that two participants were outliers for the change in DPG 
during the placebo condition. Calculating the interquartile range (IQR) identified one subject as 
an extreme (IQR*3) and the other subject as a mild outlier (IQR*1.5). When these two 
individuals are removed from the placebo analysis, then a significant negative correlation of -
0.83 (p=0.01) is observed between SOL and DPG, but not between DPG and any other sleep 
measure. 
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Table 2: Results of EEG and subjective sleep measures 
Parameter Placebo Ramelteon P Value 
    
Stage 1 (% RT) 6.0 ± 0.9 8.5 ± 1.1 0.035* 
Stage 2 (% RT) 34.4 ± 4.0 50.4 ± 3.4 0.0004* 
Stage 3/4 (% RT) 12.9 ± 2.3 11.5 ± 1.8 0.57 
REM (% RT) 9.6 ± 1.7 8.5 ± 1.4 0.45 
Wakefulness (% RT) 37.2 ± 6.8 21.0 ± 4.3 0.02* 
SOL (min) 8.1 ± 1.2 6.5 ± 1.0 0.33 
WASO (min) 82.2 ± 15.7 45.7 ± 9.6 0.01* 
TST (min) 150.7 ± 16.2 193.9 ± 10.8 0.02* 
Subjective TST (min) 101.5 ± 15.4 177.5 ± 20.5 0.002* 
 
Sleep stages and % wakefulness are expressed relative to the 240 minute sleep opportunity 
recording time (RT). *denotes a significant value using the modified Bonferonni correction (p < 
0.047). 
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Figure 3:  Correlation between SOL and the DPG 
SOL (3 continuous epochs to sleep) and the DPG were correlated such that a greater change in 
DPG was associated with a shorter SOL in the ramelteon condition (B) compared to placebo 
condition (A).  The lines represent the best linear fit through the data. 
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Discussion 
Administration of the melatonin MT-1/MT-2 agonist ramelteon (8mg) 2 h prior to a 
daytime sleep opportunity reduced CBT, increased the DPG, initially increased and then 
decreased proximal skin temperature, and improved daytime sleep relative to placebo.  
Ramelteon improved daytime sleep as measured by increases in TST, stages 1 and 2 sleep, and a 
decrease in WASO.  Ramelteon has been reported to significantly reduce SOL at night (Zammit, 
Schwartz et al. 2009).  We did not find a significant reduction in SOL in the ramelteon condition, 
perhaps due to a floor effect as we tested healthy young individuals without sleep problems 
during an afternoon sleep opportunity.  The attenuation of the circadian rise in CBT following 
ramelteon administration was accompanied by changes in skin temperature as determined by 
proximal skin temperature and the DPG.  Finally, the magnitude of the increase in the DPG and 
distal skin temperature were correlated with a faster latency to sleep in the ramelteon condition.  
Together with findings from previous studies that have demonstrated a hypothermic 
effect of melatonin (Dawson, Gibbon et al. 1996; Reid, Van den Heuvel et al. 1996; Hughes and 
Badia 1997; Satoh and Mishima 2001), the current findings suggest that the sleep promoting 
effect of ramelteon may be mediated in part through its ability to lower CBT. The magnitude of 
change in CBT observed with ramelteon administration was similar to what has been reported 
with exogenous melatonin (Hughes and Badia 1997).  Perhaps more important to the initiation of 
sleep is the finding that ramelteon caused an increase in distal skin temperature and the DPG, as 
the latter has been shown to predict SOL (Krauchi, Cajochen et al. 2000).  We also found a 
greater change in the DPG and distal skin temperature to be associated with less stage 1sleep and 
a greater change in distal skin temperature to be associated with more stage 3/4 sleep.  Previous 
research findings have demonstrated an increase in slow wave sleep in young and older 
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individuals following skin warming (Raymann, Swaab et al. 2008).  The present study provides 
further evidence that changes in skin temperature are associated with changes in sleep staging. 
Melatonin and melatonin analogues appear to primarily influence skin blood flow as 
compared to other circulatory beds such as cerebral blood flow (van der Helm-van Mil, van 
Someren et al. 2003).  Heat loss after the administration of exogenous melatonin has been 
reported to occur through vasodilation of peripheral skin blood vessels, presumably arterial-
venous anastomoses in the hands and feet (Aoki, Stephens et al. 2006; Aoki, Zhao et al. 2008). 
The opening of these important thermoregulatory sites facilitates a high level of blood flow to 
the skin, thus creating a positive thermal gradient with the environment and allowing for the 
convective exchange of heat to occur (Charkoudian 2003).  It is unclear mechanistically how 
ramelteon or melatonin are able to modulate skin temperature.  It is possible that both the 
sympathetic noradrenergic vasoconstrictor and non-adrenergic active vasodilator systems that are 
involved in temperature regulation during cold and heat stress, respectively, contribute to the 
thermoregulatory changes observed (Charkoudian 2003).  For example, it has been reported that 
daytime exogenous melatonin administration reduces the thermoregulatory set-point for 
vasoconstriction during whole body cooling (Aoki, Zhao et al. 2008).  Additionally, whole body 
warming has been reported to result in a lower internal threshold for activation of the active 
cutaneous vasodilator system following melatonin administration (Aoki, Stephens et al. 2006).  
Further, in the rat caudal artery (an important site for thermoregulation), melatonin potentiated 
the vasoconstrictor response to an α-adrenergic agonist through MT-1 receptor activation, while 
causing vasodilation through MT-2 receptor activation (Masana, Doolen et al. 2002).  Taken 
together, these data suggest melatonin and/or melatonergic analogues may modulate temperature 
through central mediated changes in sympathetic outflow as well as peripheral activation of the 
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membrane bound MT-1 and MT-2 receptors located on the smooth muscle cells of the 
vasculature. 
The time course of the effects of ramelteon on CBT and proximal skin temperature 
suggests that thermoregulatory effects are first observed near the reported time of peak ramelteon 
concentration, approximately 45 minutes following administration (Kato, Hirai et al. 2005).  It is 
unknown specifically how changes in skin and core temperature are mechanistically involved 
with initiating and/or maintaining sleep.  An increase in skin temperature may stimulate 
thermosensitive  nerve endings located in the skin (Van Someren 2000; Lowry, Lightman et al. 
2009), the preoptic anterior hypothalamus (POAH) (Van Someren 2000), interfascicular part of 
the dorsal raphe nucleus (Cronin and Baker 1977; Werner and Bienek 1985; Lowry, Lightman et 
al. 2009), or other thermosensitive brain centers.  Stimulation of these temperature sensitive 
neural circuits may affect sleep promoting brain areas and/or inhibit wakefulness-promoting 
brain areas.  It has been demonstrated that cutaneous warming of proximal skin via a liquid 
filled, temperature controlled whole body thermosuit resulted in a decrease in SOL by 27% 
(Raymann, Swaab et al. 2005).  Additionally, an effect of temperature manipulation on the neural 
activity of brain centers thought to be involved in sleep and wakefulness has been reported.  
Specifically, a subpopulation of warm-sensitive POAH neurons spontaneously increases its 
firing rate at sleep onset and experimental warming of the POAH induces a similar increase in 
this firing rate (McGinty and Szymusiak 1990; Alam, Szymusiak et al. 1995; McGinty, Alam et 
al. 2001).  Further, POAH thermosensitive neurons have been shown to affect the discharge rate 
of neurons located in areas known to regulate sleep and wakefulness (Alam, Szymusiak et al. 
1995).  It has been proposed that a positive feedback loop exists where changes in CBT and heat 
loss both trigger and reinforce sleep onset (Van Someren 2000; Gilbert, van den Heuvel et al. 
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2004).  In this model, a reduction in the thermoregulatory set point that occurs during the 
transition from wakefulness to sleep results in further heat loss and a sustained reduction in CBT.  
Our findings are in agreement with previous research showing that changes in CBT may be less 
associated with decreases in SOL as compared to changes in skin temperature in younger and 
older adults (Raymann, Swaab et al. 2005; Raymann and Van Someren 2008).   
 Ramelteon may also influence sleep physiology by binding to melatonin receptors in the 
central nervous system.  As noted, melatonin’s actions are mediated by two G-protein coupled 
receptor subtypes termed the MT-1 and MT-2 receptors (Dubocovich 2007). It has been 
hypothesized that the sleep promoting response is mediated by the MT-1 receptor subtype 
(Dubocovich 2007).  Binding of melatonin to MT-1 receptors on the suprachiasmatic nucleus 
(SCN) is reported to inhibit SCN electrical activity (Liu, Weaver et al. 1997; Jin, von Gall et al. 
2003). The SCN projects to wakefulness and sleep promoting brain regions and thus ramelteon 
may promote sleep during the biological daytime by inhibiting the circadian arousal signal 
(Hughes and Badia 1997; Sack, Hughes et al. 1997).  In contrast, when endogenous melatonin 
levels are high, ramelteon has less influence on sleep physiology, except for reductions in sleep 
latency (Roth, Stubbs et al. 2005).  It is also possible that ramelteon promotes sleep during the 
biological day via binding to MT-2 receptors.  The selective MT-2 analogue IIK7 is reported to 
promote NREM sleep in rats (Fisher and Sugden 2009), thus challenging the previously held 
assumption of discrete MT-1 and MT-2 receptor mediated effects.  
To our knowledge, there have been no published studies in which ramelteon has been 
compared to melatonin on any outcome measure.  Such a comparison between melatonin and its 
analogues could be useful.  We believe that the future development of selective melatonin 
receptor agonists may provide more precise determination of the influence of melatonin receptor 
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subtypes on human physiology.  This ultimately may lead to more targeted therapies. 
It is unclear why two of the participants when receiving placebo had a large DPG.    
Removing these individuals resulted in a significant correlation between DPG and SOL for the 
placebo condition.  It is worth noting that in the placebo condition, only two participants had a 
DPG greater than 2 degrees Celsius whereas more than half of participants had a DPG greater 
than 2 degrees Celsius in the ramelteon condition.  Thus, ramelteon appears to have increased the 
magnitude and variance in the change of the DPG, increasing the likelihood of observing a 
significant relationship between the DPG and SOL (Zammit, Schwartz et al. 2009). 
In conclusion, ramelteon improved objective and subjective markers of sleep during a 
daytime sleep episode.  These effects were associated with thermoregulatory adjustments 
observed in response to ramelteon administration.  The findings that ramelteon improves sleep 
during the biological day suggests that ramelteon may have potential as a therapeutic target for 
the treatment of insomnia associated with circadian rhythm sleep disorders in which sleep occurs 
at inappropriate biological times.  
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Abstract 
Exogenous melatonin has been shown to improve daytime sleep. These improvements in sleep 
are thought to be partly mediated by melatonin induced thermoregulatory changes in core body 
temperature (CBT) and peripheral heat loss. It is also possible that melatonin may facilitate 
daytime sleep by reducing resting metabolic rate (RMR). Therefore, we tested the hypothesis 
that exogenous melatonin (5mg) would acutely decrease RMR as assessed by volume of oxygen 
consumption (VO2), and calculated energy expenditure (REE) when compared to placebo. We 
studied eighteen healthy adults (7 females), BMI (22.5 ± 1.7 kg/m2) aged (22 ± 5 yrs) in a 
randomized, double-blind, placebo-controlled study.  Participants were studied under modified 
constant routine conditions to control for influences of activity, posture, and lighting.  
Melatonin/placebo was administered 1.25h after awakening from a 5h daytime sleep opportunity 
while in the fasted state.  Resting VO2 was assessed using indirect calorimetry (Truemax, 
Parvomedics) just prior to pill administration, and twice after (60 and 90 min). Additionally, 
REE expressed as kilocalories per minute (kcal/min) was calculated for each test. Changes in 
metabolic measures were calculated as differences from baseline by repeated measures ANOVA.  
As hypothesized, exogenous melatonin significantly decreased VO2 (ml/kg/min) and REE 
(kcals/min) (P<0.05). Together with previous research findings that have shown 
thermoregulatory effects of melatonin on CBT and skin temperatures these findings suggest that 
melatonin, may also facilitate sleep through reductions in RMR.  
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Introduction 
The sleep and thermoregulatory systems have evolved together  (Campbell 1984; Zepelin 
2000)  and are temporally associated such that sleep is best when initiated on the circadian 
decline of core body temperature (CBT) and following the nocturnal increase in peripheral heat 
loss (Zulley, Wever et al. 1981; Campbell and Broughton 1994; Murphy and Campbell 1997; 
Krauchi, Cajochen et al. 2000). Temperature signals from the periphery and the core are 
integrated in the preoptic area of the anterior hypothalamus (POAH).  Activation of warm 
sensitive neurons in the POAH by central and peripheral afferents evoke thermoregulatory 
responses similar to that which is normally observed during sleep onset at night. 
Sleep/wakefulness active neurons are also located in areas of the POAH and their circuitry 
overlap with the thermoregulatory system (Kumar, Vetrivelan et al. 2007) and have been shown 
to be responsive to changes in temperature. Specifically, McGinty and Szymusiak examined 
warm sensitive neurons in the POAH of rats and found that their activity increased at sleep onset  
(McGinty and Szymusiak 2001).  Additionally, preoptic warming in the cat promoted EEG slow-
wave activity during sleep (Roberts and Robinson 1969), decreased the discharge rate of wake 
active neurons in the lateral hypothalamus (Methippara, Alam et al. 2003) serotonergic neurons 
in the dorsal raphe nucleus (DRN) (Guzman-Marin, Alam et al. 2000), and evoked behavioral 
and electrographic signs of sleep in rats (Benedek, Obal et al. 1982). These findings suggest that 
temperature afferent signals may influence the timing and quality of sleep.  
Melatonin is a hormone that is controlled by the master circadian clock in the 
suprachiasmatic nuclei (SCN) and is released during the biological night with the onset occurring 
on average 2 hours prior to sleep (Wright, Gronfier et al. 2005). Melatonin receptors have been 
identified in several brain areas involved with sleep and thermoregulation including: the SCN, 
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POAH, and throughout the cortex (Stankov, Cozzi et al. 1991) as well as the peripheral 
vasculature (Ekmekcioglu, Haslmayer et al. 2001; Masana, Doolen et al. 2002; Ekmekcioglu, 
Thalhammer et al. 2003). In humans, the nocturnal increase in endogenous melatonin is 
associated with an increase in sleep propensity, a decrease in CBT, and an increase in peripheral 
heat loss (Krauchi, Cajochen et al. 1999). During the daytime when endogenous levels are low, 
the administration of exogenous melatonin or a melatonin analogue produces similar 
physiological changes (Markwald, Lee-Chiong et al. ; Reid, Van den Heuvel et al. 1996; Gilbert, 
van den Heuvel et al. 1999; Harris, Burgess et al. 2001).  In fact, improved daytime sleep with 
exogenous melatonin or an analogue is thought to be partly mediated by the increase in 
peripheral heat loss and reduction in CBT (Markwald, Lee-Chiong et al. ; Krauchi, Cajochen et 
al. 1999).  The mechanism by which melatonin affects the thermoregulatory system is not known 
but may be a result of central binding to MT1 and MT2 receptors in the brain, in the peripheral 
circulation, or both. Findings from these research studies suggest that melatonin may be 
functionally important to the nocturnal regulation of sleep and body temperature.  
In addition to its ability to increase peripheral heat loss, it is also possible that melatonin 
may facilitate daytime sleep by reducing resting metabolic rate (RMR) and arousal. A reduction 
in RMR, if uncompensated for would reduce heat production and consequently lower CBT. 
Further, previous research findings have demonstrated that under controlled constant routine 
conditions, there is a circadian rhythm to heat production, with the trough occurring between 4-5 
hours (Krauchi and Wirz-Justice 1994), and ~8 hours (Spengler, Czeisler et al. 2000) prior to the 
CBT minimum. It is possible that the rhythm of endogenous melatonin contributes to the 
observed circadian variation in REE. Therefore, we tested the hypothesis that exogenous 
melatonin (5mg) would acutely decrease RMR as assessed by volume of oxygen consumption 
67 
 
(VO2), and calculated resting energy expenditure (REE) when compared to placebo during the 
biological daytime when endogenous melatonin levels are low and CBT is high. 
 
Methods 
Subjects 
A total of eighteen healthy adults, BMI (23 ± 2 kg/m2) aged (22 ± 5yrs) completed the 
study. Potential subjects underwent a comprehensive medical evaluation at the Clinical and 
Translational Research Center (CTRC) at the University of Colorado – Boulder.  Participants 
were admitted into the study once they were considered free of any medical conditions as 
determined by medical history, physical exam, blood and urine chemistries, 12-lead clinical 
electrocardiogram, and toxicology screens for drug use.  Screening procedures also involved 
sleep disorder questionnaires and psychological testing to ensure participants were free from 
such problems.  A prior diagnosis of a sleep or psychiatric disorder was also exclusionary.  
Potential participants were excluded if they were smokers, had not lived at Denver altitude for at 
least 3 months, had a habitual sleep duration outside of <7 and >9 range, or took any 
medications. This study was approved by the University of Colorado - Boulder Institutional 
Review Board and the Scientific Advisory & Review Committee of the Colorado Clinical and 
Translational Sciences Institute.  Participants gave written-informed consent, and all procedures 
were performed according to the Declaration of Helsinki.   
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Study Design 
The study was a randomized, double-blind and placebo-controlled research design. This 
study was part of a larger research protocol examining the phase resetting response to exogenous 
melatonin. The protocol required participants to live for 3.7 days in the Sleep and Chronobiology 
Laboratory.  The laboratory visit was preceded by a one week ~8h consistent sleep-wakefulness 
schedule verified by call-ins to a time stamped recorder, actigraphy (Mini Mitter, Respironics, 
Bend, OR) and sleep logs. Additionally, participants refrained from caffeine, nicotine, and over-
the-counter drugs for the duration of the study.  An alcohol breath tester and urine drug screen 
verified that subjects were free of drugs upon admission to the laboratory. Pill administration 
was double-blind and randomized such that, participants received either melatonin (5 mg) or a 
rice-filled placebo. 
 
Experimental Procedures 
Participants were studied under modified constant routine conditions to control for 
influences of activity, posture, and lighting. Ambient temperature was held constant within the 
thermoneutral range of (22-24°C). Participants were awoken from a 5 hour daytime sleep 
opportunity and remained in a fasted state until all metabolic measurements were complete. 
Additionally, participants were not allowed to get up from the bed during metabolic testing and 
kept a constant supine position. The pill, either melatonin or placebo was administered 1.25h 
upon awakening in the late afternoon.  See Figure 1 for a more detailed protocol timeline. 
Metabolic testing was performed once before the pill and two times post pill ingestion.  
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Figure 1: Protocol Timeline 
Following a 5 h daytime sleep opportunity resting metabolic rate (RMR) was assessed once at 
baseline, and twice more following either the ingestion of melatonin (5 mg) or placebo. The 0 
point denotes end of sleep opportunity. The pill was given 1 h and 15 minutes after awakening. 
Filled triangles represent RMR assessments. Post pill assessments began at 45 and 60 minutes 
after pill intake, or (2 h, and 2 h and 15 min after awakening, respectively). 
 
 
 
 
 
 
 
 
 
 
 
0      1.0  1.25 2.0 2.25 2.5
End RMR Testing Pill Administration
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Metabolic Assessment 
Resting metabolic rate (RMR) was examined by the measurement of the volume of 
oxygen consumed (VO2)  via the indirect calorimetry technique (Frankenfield and Coleman 
2009). A metabolic cart (Parvo Medics Truemax 2400, Salt Lake City, UT) was used to assess 
the percentage of fractional expired oxygen (O2) via paramagnetic analyzers and percentage of 
fractional expired carbon dioxide (CO2) via infrared analyzers.  Gas analyzers compare the 
sampled air to the known concentrations of the reference air. This technique is the gold standard 
for assessing changes in metabolism through changes in cellular oxygen consumption instead of 
heat production (a more expensive and impractical technique).  A clear plastic ventilated hood, 
or alternatively, a mouthpiece connected to a 3-way valve in conjunction with nose clips were 
used to collect expired air from the participants. The method of collection was kept consistent for 
each participant. A hose connected the hood (or mouthpiece) to oxygen and carbon dioxide 
analyzers. The metabolic cart was always calibrated ~30 min prior to the baseline assessment.  
The gas analyzers were calibrated with known concentrations of CO2 and O2 and the flow rate 
was calibrated using a 3.0 L syringe. One 15 minute baseline RMR was conducted with two 
more assessments beginning at 45 and 60 minutes post pill administration. VO2 relative to body 
weight in milliliters per kilogram per minute (ml/kg/min) and the respiratory quotient (RQ) were 
assessed on a breath by breath basis for 15 minutes. The first five minutes of data collected were 
discarded to account for initial changes in ventilation as the participants became accustomed to 
either the ventilated hood or mouthpiece and nose clips. The last 10 min of the RMR assessment 
was averaged and used for the analysis. Resting energy expenditure (REE) in kilocalories per 
min (kcals/min) was then calculated from VO2 and the RQ based on the equations of (Jequier and 
Felber 1987). 
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Statistical Analysis  
The effects of melatonin and placebo on the metabolic variables measured were 
compared using repeated-measures analyses of variance (ANOVA).  A difference from baseline 
was calculated to account for inter-individual differences in baseline RMR. Data are expressed as 
means ± S.E.M.  
 
Results 
Metabolic Data 
Repeated measures ANOVA revealed that exogenous melatonin (5 mg) significantly 
reduced VO2 (Figure 2a) and calculated REE (Figure 2b) as compared to baseline. VO2 (F(1, 
16)=8.98, p = 0.009 and REE were significantly lower in the final assessment than in the second 
assessment for the melatonin group. No significant difference was observed within the placebo 
group or between the melatonin and placebo groups. Additionally, there were no differences in 
the respiratory quotient (RQ) between groups or assessments (Figure 3).  
 
Discussion 
The finding from this study is that exogenous melatonin (5 mg) acutely lowered RMR 
during the late afternoon when endogenous melatonin levels are low. These data suggest that the 
onset of the circadian melatonin rhythm at night may promote a state of reduced arousal during 
this circadian time in part by reducing energy expenditure.  
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Figure 2: Effect of melatonin on VO2 and REE 
 
Values expressed as means ± SEM. Open circles represent the placebo group and closed circles 
represent the melatonin group. The 0 point denotes the time that melatonin or placebo was 
administered.  Each metabolic assessment lasted for 15 minutes (beginning at 45 and 60 min post 
pill). (A) Melatonin (5 mg) significantly reduced VO2 relative to baseline. (B) Melatonin (5 mg) 
significantly reduced REE relative to baseline. The * denotes a significant difference from the 
second metabolic assessment.  
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Figure 3: Effect of melatonin on RQ 
Values expressed as means ± SEM. Open circles represent the placebo group and closed circles 
represent the melatonin group. The 0 point denotes the time that melatonin or placebo were 
administered.  Each metabolic assessment lasted for 15 minutes (beginning at 45 and 60 min post 
pill). 
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These data also demonstrate another mechanism by which changes in temperature may be 
interpreted by our brain in order to initiate and/or maintain sleep. It is well known that sleep is 
best when initiated on the downward arm of the core body temperature (CBT) rhythm (Czeisler, 
Weitzman et al. 1980; Zulley, Wever et al. 1981). Furthermore, it is known that both heat loss 
and heat production contribute to the circadian rhythm in CBT, with heat loss more of a 
contributing factor to the evening circadian reduction in CBT than heat production (Krauchi and 
Wirz-Justice 1994). This does not preclude endogenous melatonin from a potential role in CBT 
regulation during the night however, via small changes in REE. A melatonin-initiated reduction 
in heat production may contribute to the observed nocturnal decline in CBT and serve as an 
additional thermoregulatory signal in the regulation of sleep and wakefulness. The observed 
acute reduction in metabolic rate in the current study may be a reflection of a central effect of 
melatonin to reduce arousal, or a direct effect on thermoregulatory processes to reduce CBT. 
Future research protocols will need to focus on the contribution of the observed reduction in 
RMR to melatonin in conjunction with core and skin thermoregulatory variables.   
The magnitude of the effect of melatonin on RMR is relatively small; however this 
change may still be meaningful with regards to the physiology preceding sleep at night. 
Preliminary data from our laboratory demonstrate a circadian variation in 24 hour REE with a 
magnitude of ~0.3 Kilocalories/minute from peak to trough (Jung CM, Chaker Z et al. 2010). 
Furthermore, the trough occurred ~5.5 hours before the CBT minimum around the time of 
habitual bedtime. The results from the current study suggest that the onset of the circadian 
endogenous melatonin rhythm may account for ~1/3rd of the circadian variation in 24 hour REE. 
This may promote a state of reduced arousal during habitual bedtime in part by reducing REE. 
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There were several limitations associated with this study.  Melatonin did not elicit a 
significant change in REE from the placebo group.  In the future, the use of a within subjects 
experimental design may be a more sensitive approach for detecting small changes in REE.  
Further, this was part of a larger research protocol that involved a level of prior sleep 
deprivation. The effect of prior sleep deprivation on metabolic physiology is not known and may 
have impacted these data, however all subjects underwent the same experimental conditions.  
Future studies should also examine thermoregulatory variables (i.e. CBT and skin temperatures) 
in conjunction with the effect of daytime exogenous melatonin on metabolic physiology.  
In conclusion, exogenous melatonin (5mg) decreased resting VO2 and REE when 
compared to placebo. Together with previous research findings that have shown 
thermoregulatory effects of exogenous melatonin on CBT and skin temperatures, these findings 
suggest that melatonin may also facilitate sleep through reductions in REE. 
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Abstract 
 
The sleep and thermoregulatory systems are temporally connected such that a decrease in core 
body temperature (CBT) and an increase in peripheral heat loss occur prior to sleep onset in 
individuals entrained to the light/dark cycle. Further, sleep quality is best when sleep is initiated 
under these thermoregulatory conditions.  Caffeine and bright light exposure are reported to 
disrupt sleep.  Bright light has been reported to impact skin temperature physiology yet it is 
unknown if caffeine impacts skin temperature physiology during the time of habitual sleep onset.  
Also unknown is whether the combination of bright light and caffeine impacts skin temperature 
physiology more than does either bright light or caffeine alone.  Therefore, we investigated the 
effects of caffeine and bright light (two common pharmacological and environmental factors) on 
sleep and thermoregulatory physiology during a modified constant routine protocol. Subjects 
completed four laboratory visits in which they were randomly assigned to receive either bright 
light (~3000 lux) or dim light (~1.5 lux) during the time of habitual sleep onset.  Within each 
lighting condition subjects ingested either caffeine (2.9mg/kg) or placebo in a double blind 
fashion, three hours before light exposure began. Results showed that caffeine attenuated the 
nocturnal fall in CBT, delayed the circadian increase in peripheral heat loss as assessed by distal 
temperature and the distal to proximal skin gradient. Furthermore, the combination of bright light 
and caffeine reduced the amount of slow wave sleep and increased sleep onset latency. These 
data demonstrate that the sleep and thermoregulatory systems are impacted individually and in 
combination by caffeine and bright light.  
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Introduction 
From an evolutionary perspective, the processes of sleep and thermoregulation have co-
evolved in endotherms (Zepelin 2000). The primary nuclei controlling sleep and 
thermoregulation sit in close proximity to one another in the anterior hypothalamus and have 
overlapping neural circuitry (for reviews see (Van Someren 2000; Saper, Scammell et al. 2005; 
Kumar, Vetrivelan et al. 2007; Szymusiak, Gvilia et al. 2007). Physiologically, the two processes 
are temporally associated such that a decrease in core body temperature (CBT) and an increase in 
peripheral heat loss occur prior to sleep onset in individuals entrained to the light/dark cycle 
(Dijk and von Schantz 2005). Sleep quality is best when sleep is initiated under these 
thermoregulatory conditions. Research findings have demonstrated that the nightly increase in 
peripheral heat loss is a predictor variable for how quickly an individual will fall asleep 
(Krauchi, Cajochen et al. 2000). People often maintain wakefulness several hours into the night 
in response to work, family and social demands. This behavior is facilitated with the emergence 
of artificial lighting, and the development of readily available central nervous stimulants such as 
caffeine.  
Caffeine is the world’s most widely consumed stimulant (Nawrot, Jordan et al. 2003), 
and it has been estimated that the mean daily intake is 4 mg/kg body weight or approximately 
280 mg for a 155 pound individual (Barone and Roberts 1996). Caffeine has been shown to have 
a negative effect on sleep as evidenced by a reduction in slow wave sleep, longer sleep onset, 
shortened total sleep time, decreased sleep efficiency and decreased stage 2 sleep (Okuma, 
Matsuoka et al. 1982; Landolt, Dijk et al. 1995; Drapeau, Hamel-Hebert et al. 2006). Caffeine is 
an adenosine receptor antagonist and is thought to increase arousal via binding to adenosine A2A 
receptors (Huang, Qu et al. 2005). Adenosine is a byproduct of energy metabolism; breakdown 
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of ATP, and adenosine accumulates in the brain with time spent awake since the previous sleep 
episode (Porkka-Heiskanen, Strecker et al. 1997). Additionally, adenosine has been shown to 
increase the firing rate of sleep promoting neurons in the ventral lateral preoptic area (VLPO), a 
key neural center in the regulation of sleep/wakefulness (Morairty, Rainnie et al. 2004). Caffeine 
may therefore increase arousal by inhibiting A1 and A2a receptors on the VLPO, thereby 
inhibiting the gradual increase in sleep pressure normally evoked as adenosine levels rise. 
Additionally, caffeine may affect sleep by reducing adenosine-mediated increases in nightly 
melatonin levels in the pineal gland (Gharib, Reynaud et al. 1989). Finally, caffeine has been 
shown to attenuate the circadian fall in core body temperature (CBT) observed during the 
biological night (Wright, Badia et al. 1997; Wright, Myers et al. 2000), and this may be one more 
mechanism by which caffeine interacts with the regulation of sleep/wakefulness. 
 
Bright light at night has been shown to suppress endogenous levels of melatonin (Lewy, 
Wehr et al. 1980; McIntyre, Norman et al. 1989), attenuate the circadian fall in the CBT rhythm 
compared to dim light (Badia, Myers et al. 1991; Dijk, Cajochen et al. 1991; Wright, Badia et al. 
1997; Burgess, Sletten et al. 2001; Cajochen, Munch et al. 2005) and decrease peripheral heat 
loss (Cajochen, Munch et al. 2005). In humans, during the biological night, the increase in 
melatonin is associated with a decrease in CBT, an increase in distal skin temperature, and a 
decrease in the distal to proximal skin temperature gradient (DPG) (Krauchi, Cajochen et al. 
1999; Krauchi, Cajochen et al. 2000). The DPG is considered a marker of peripheral blood vessel 
tone where a smaller temperature difference measured between distal skin sites to proximal skin 
sites indicate heat loss via an increase in blood flow to the peripheral cutaneous circulation  
(Rubinstein and Sessler 1990). 
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The impact of caffeine on skin temperature physiology during the time of habitual sleep 
onset and the compound effect of bright light and caffeine together on sleep and 
thermoregulatory physiology is unknown. Therefore the present study sought to investigate the 
individual and combined effects of caffeine and bright light on skin temperature regulation and 
sleep in individuals during a modified constant routine protocol.  We hypothesized that caffeine 
would act individually and in combination with bright light to attenuate the circadian fall in core 
temperature, attenuate the circadian rise in the DPG during the time of habitual bedtime, as well 
as increase SOL and decrease slow wave sleep during a nighttime sleep opportunity. 
 
Methods 
Subjects 
 Five (3 women, 2 men) young (mean age ± SE) = 24 ± 4 years and with normal body 
mass indexes (24.0 ± 1.0 kg/m2) participated. Subjects underwent a medical evaluation at the 
Clinical and Translational Research Center (CTRC) at the University of Colorado – Boulder. 
Participants were admitted into the study once they were considered free of any medical 
conditions as determined by medical history, physical exam, blood and urine chemistries, 12-
lead clinical electrocardiogram, and toxicology screens for drug use.  Screening procedures also 
involved sleep disorder questionnaires and psychological testing to ensure subjects were free 
from such problems.  A prior diagnosis of a sleep or psychiatric disorder was also exclusionary.  
Potential subjects were excluded if they were smokers, had not lived at Denver altitude for at 
least 3 months, had a habitual sleep duration outside of <7 and >9 range, or need to take or were 
taking any medications. This study was approved by the University of Colorado - Boulder 
Institutional Review Board and the Scientific Advisory & Review Committee of the Colorado 
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Clinical and Translational Sciences Institute.  Subjects gave written-informed consent, and all 
procedures were performed according to the Declaration of Helsinki. 
 
Design 
 A randomized, within-subject, crossover, and placebo-controlled research design was 
used in which participants came to the Sleep and Chronobiology Laboratory for 4 separate visits, 
each separated by one week. Each laboratory visit was preceded by a one week consistent sleep-
wakefulness schedule verified by call-ins to a time stamped recorder, actigraphy recordings 
(Actiwatch-L, Mini Mitter Respironics, Bend, OR) and sleep logs. Subjects refrained from 
caffeine, nicotine, and over-the-counter drugs for two weeks preceding the first laboratory visit 
and throughout the duration of the study. Compliance was checked with urine toxicology and 
breath alcohol testing (Lifeloc Technologies Model FC10, Wheat Ridge, CO) at the beginning of 
each lab visit.  
 Subjects visited the laboratory for each of the following four conditions: (dim-light + 
placebo, dim-light + caffeine, bright-light + placebo, bright-light + caffeine). Caffeine and 
placebo administration were double-blind. Computerized implementation of treatment allocation 
was performed by the CTRC pharmacist who provided pills identical in appearance in numbered 
containers. Subjects received either caffeine (2.9 mg/kg of body weight), or rice-powder filled 
placebo pills. For dim-light conditions, subjects continued to receive the same dim light exposure 
as the rest of the experimental protocol (~1.5 lux in the angle of gaze, < 8 lux maximum) and for 
the bright-light conditions, light exposure was ~3000 lux in the angle of gaze.  
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Procedures 
 This study was part of a larger research protocol examining the phase resetting response 
to bright light and caffeine.  Subjects lived in the Sleep and Chronobiology Laboratory in a 
special sleep suite that was an environment free from time cues. As part of the larger research 
protocol, subjects were sleep deprived for 40 hours and were then given an 8 h sleep opportunity 
at their habitual bedtime. Subjects were then awoken at their habitual wake-time for the 
experimental day. Exercise was prohibited for the entire protocol. Beginning at 12 hours of 
scheduled wakefulness on the experimental day, subjects were seated in bed with the head raised 
to ~35 degrees. Ambient temperature was kept stable in the thermoneutral range (22-24°Celcius). 
Continuous electroencephalography (EEG) recordings verified wakefulness. At 13 hours of 
scheduled wakefulness the pill (either caffeine or placebo) was administered. Pill administration 
was followed 3 hours later by continued dim light exposure or overhead bright light exposure for 
an additional 3 hours. See Figure 1 for a more detailed depiction of the experimental protocol. 
During light exposure, subjects were instructed to lie in the semi-recumbent supine position in 
bed, and look directly at the ceiling mounted fluorescent light source (Sylvania T8, 6500 K).  
Clear polycarbonate lenses filtered light in the UV range. Subjects fixed their gaze in the 
direction of the light source for 6 min and then were allowed free gaze for 6 minutes; this cycle 
continued for the entire 3 hours of light exposure. Once light exposure was complete, the lights 
were turned off for a 5 hour sleep opportunity. Thus, sleep was attempted 3 hours after habitual  
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Figure 1: Protocol Timeline  
A schematic depiction of the entire experimental day with an additional specific focus on the pill 
and light treatment period. Representative timeline based on a 12AM – 8AM sleep/wake 
schedule. Subjects were awoken at habitual wake time and spent the day sitting or lying in bed 
until one hour prior to the pill was administered. At this point, subjects were told to remain in 
bed, in a semi-recumbent supine position for the remainder of the experimental day (constant 
posture). The X denotes pill administration (caffeine or placebo), and the triangle denotes 
beginning of light exposure. Light exposure began 3 hours after pill administration and occurred 
for 3 hours before the lights were turned off for a 5 hour sleep opportunity. Subjects were then 
awoken at their habitual wake time. 
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bedtime. Sleep laboratory staff continually monitored subjects to ensure that the protocol was 
followed.  
 
Assessment of core and skin temperatures 
Core body temperature (CBT) was measured with a temperature pill that was ingested 
and transmitted internal temperature via radio frequency to an external unit placed around the 
participant’s waist (Vital Sense, Mini Mitter Respironics, Bend OR). Proximal and distal skin 
temperatures were measured via thermopatches placed inferior to the left clavicle, at the location 
of the subclavian vein (Sub) and the top of the left dorsal foot (Foot) respectively. The DPG was 
calculated as the difference between the Foot and Sub thermopatches. Core and skin body 
temperatures were analyzed for 7 continuous hours beginning 30 minutes before the pill was 
ingested and ending 30 minutes after the lights were turned off for the sleep opportunity.  
 
Assessment of EEG recordings   
Sleep recordings were obtained with Siesta digital sleep recorders (Compumedics USA 
Ltd, Charlotte, NC) using monopolar EEGs referenced to contra-lateral mastoids according to the 
International 10-20 system (C3-A2, C4-A1, O1-A2, F3-A2), right and left electrooculograms 
(EOG), chin electromyograms (EMG) and electrocardiogram (ECG). Impedences were below 5 
kohms. Data were stored and sampled at a rate of 256 samples per second per channel with a 12-
bit A-D board. High and low pass digital filters for EEG and EOG were set at 0.10 and 30 Hz, 
respectively. High and low pass digital filters for EMG were set at 10 and 100 Hz, respectively. 
Sleep was scored according to standard guidelines from brain region C3-A2 (insert 
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Rechtschaffen A 1968). Sleep onset latency (SOL) was defined as the time from lights out to the 
onset of three continuous epochs of EEG defined sleep.  
 
Assessment of subjective sleepiness 
 Subjective sleepiness was assessed using the Karolinska Sleepiness Scale (KSS). A 
baseline KSS was given at the time of pill administration and every hour post pill administration 
for 5 hours. 
 
Data analysis 
 The primary outcome variables for body temperature were CBT and the DPG. Data for 
each body temperature measure were averaged into 10-minute bins. A two stage mixed model 
analysis was performed on each of the measures. Differences from an average 10 minute 
baseline preceding pill administration and light exposure were calculated for distal and proximal 
skin temperature sites as well as the DPG and CBT to control for differences in baseline body 
temperature levels between laboratory visits.  To determine the initial effect of caffeine on 
thermoregulatory variables, the two caffeine and the two placebo conditions were averaged 
together for the first 3 hours of assessment. Data from two individuals for one condition were not 
available for the foot, subclavian, or DPG analysis due to equipment malfunction. The primary 
outcome variables for sleep were SOL and slow wave sleep. Data are expressed as mean ± 
standard error of the mean (SEM) 
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Results 
 
 
Core and skin temperatures 
The caffeine conditions significantly attenuated the circadian fall in CBT (Fig 2A) and 
significantly delayed the circadian increase in DPG (Fig 2D) compared to the placebo conditions.  
The mixed model ANOVA revealed a significant main effect of time and interaction of drug by 
time for foot and DPG measures, and a drug by time interaction for CBT (Table 1). For bright 
light treatment, the mixed model ANOVA revealed a significant main effect of time for CBT, 
Sub, and the DPG (Table 2). For difference from pill administration baseline, planned 
comparisons revealed a significant difference for the core temperature measure between the 
caffeine and placebo conditions at 165 minutes post pill ingestion, see Figure 3a. For difference 
from light exposure baseline, planned comparisons revealed a significant difference for the Sub 
temperature measure between the bright light-placebo condition and both caffeine conditions at 
15 minutes after light exposure began and for Sub between bright light placebo and dim light-
caffeine conditions for a majority of the light exposure session (Figure 3b) (P < 0.05). 
 
Sleep physiology 
There was a significant effect for condition in the SOL measure to 3 continuous epochs 
of sleep in the 5 h sleep opportunity (p = 0.03). There was also a significant condition effect for 
the percentage of PSG recorded slow wave sleep in the 5 h sleep opportunity (p = 0.03). Planned 
comparisons revealed a significant difference in SOL from the bright light-placebo and dim 
light-placebo conditions from the bright light-caffeine condition. There was a significant 
difference for stage 3/4 sleep for the bright light-caffeine condition from the bright light-placebo  
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Table 1: ANOVA Results for thermoregulatory effects of caffeine on body temperatures 
following pill administration 
 
Measure Caffeine Time CxT 
    
CBT 
F(1,6)=4.13, 
p=0.11 
F(5,180)=1.36,  
p=0.28 
F(5,180)=6.64, 
p=0.001* 
DPG 
F(1,6)=0.18, 
p=0.69 
F(5,180)=13.14, 
p<0.001* 
F(5,180)=7.21, 
p=0.001* 
Sub 
F(1,6)=0.07 
P=0.80 
F(5,180)=2.33 
P=0.09 
F(5,180)=0.16 
P=0.98 
Foot 
F(1,6)=0.07 
P=0.81 
F(5,180)=19.80 
P<0.0001 
F(5,180)=6.12 
P=0.002* 
*denotes a significant value from placebo conditions. 
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Table 2: ANOVA results for thermoregulatory effects of caffeine and bright light following  
Light exposure. 
 
 
 
 
 
 
 
 
*denotes a significant main effect of time 
 
 
 
 
 
 
 
 
Measure Condition Time CxT 
    
CBT F(3,6)=1.16, 
p=0.37 
F(5,180)=15.91,  
p<0.0001* 
F(15,180)=0.77, 
p=0.71 
DPG F(3,6)=0.41, 
p=0.75 
F(5,180)=1.69, 
p=0.18 
F(15,180)=0.80, 
p=0.67 
Sub F(3,6)=3.15 
P=0.06 
F(5,180)=1.56 
P=0.22 
F(15,180)=0.89 
P=0.58 
Foot F(3,6)=0.20 
P=0.89 
F(5,180)=1.42 
P=0.26 
F(15,180)=0.85 
P=0.62 
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Figure 2: Thermoregulatory effects of caffeine on CBT, proximal and distal skin 
temperature sites, and the DPG following pill administration. 
 
Values expressed as means ± SEM.  The open squares represent the placebo conditions and 
closed squares represent the caffeine conditions. The 0 point denotes time that caffeine or 
placebo were administered. (A) Caffeine significantly reduced core temperature by attenuating 
the normal nighttime circadian fall as seen in placebo. (B) Proximal skin temperature measured 
at the subclavian vein (C) Distal skin temperature measured at the dorsal foot (D) The circadian 
increase in DPG was significantly attenuated after caffeine ingestion relative to placebo. * 
denotes a significant difference for caffeine from placebo conditions. 
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Figure 3: Thermoregulatory effects of caffeine and bright light on CBT, proximal and 
distal skin temperature sites, and the DPG following light exposure. 
 
Values expressed as means ± SEM.  The squares represent the placebo condition, triangles 
represent the caffeine condition, filled symbols represent the dim light condition and open 
symbols represent the bright light condition. The 0 point denotes time light exposure began. (A) 
Bright light significantly attenuated the circadian fall in CBT as seen in placebo drug and dim 
light condition. (B) Proximal skin temperature measured at the subclavian vein (C) Distal skin 
temperature measured at the dorsal foot (D) The circadian increase in DPG was significantly 
delayed after caffeine ingestion and bright light had no effect on this measure relative to placebo 
conditions. * denotes a significant difference for bright-light condition from dim light-caffeine 
and bright light-caffeine conditions. † denotes a significant difference for bright light-placebo 
from dim light-placebo. 
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and dim light-placebo conditions. There was also a significant difference in the stage 2 sleep for 
the dim-light caffeine condition from the dim light-placebo condition, and a significant 
difference in stage REM for the bright light-caffeine condition from the dim light-caffeine 
condition.  No other significant effects were observed in the mixed model for the remaining sleep 
measures (see table 3). 
 
Subjective sleep assessment 
 The mixed model ANOVA revealed a significant main effect for time (F=8.61, 
p<0.0001), a time by condition interaction (F=1.86, p=0.05), a time by subject interaction 
(F=1.83, p=0.05), and a condition by subject interaction (F=5.91, p<0.0001) on the KSS. 
Planned comparisons revealed a significant difference at hour 2 between the bright light-placebo 
and dim light-placebo conditions (Figure 4).  
Discussion 
 The primary findings from this study are as follows: Caffeine administration 6 h prior to 
a delayed nighttime sleep opportunity attenuated the circadian fall in CBT, delayed the circadian 
increase in distal skin temperature measured at the foot, and the DPG. While the interaction of 
bright light and caffeine suppressed slow wave sleep and significantly increased SOL as 
compared to either condition alone.  
 To our knowledge, this is the first study in humans to demonstrate that caffeine affects 
peripheral heat loss near habitual sleep time. Krauchi and colleagues showed that individuals  
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Table 3: Results of EEG sleep measures 
 
Parameter BL + Placebo 
BL + 
Caffeine 
DL + 
Placebo 
DL + 
Caffeine 
     
Stage 1 (% RT) 3.4 ± 1.2 3.5 ± 1.4 3.0 ± 2.4 4.7 ± 2.1 
Stage 2 (% RT) 39.4 ± 4.7 39.4 ± 9.5 40.9 ± 9.1 46.9 ± 6.2† 
Stage 3/4 
(% RT) 29.3± 6.4* 22.7 ± 3.8 27.4  ± 6.3* 24.5  ± 6.5 
REM (% RT) 22.8 ± 5.8 25.4 ± 2.9++ 22.9 ± 6.6 17.8 ± 6.0 
Wakefulness 
(% RT) 5.1 ± 2.7 9.2 ± 8.0 5.8 ± 1.4 6.0 ± 1.6 
SOL (min) -3.56 ± 3.7* 11.25 ± 6.7 -3.0 ± 1.0* 0.19 ± 2.4 
 
*    denotes a significant difference from bright light-caffeine condition 
†    denotes a significant difference from dim light-placebo condition 
++   denotes a significant difference from dim light-caffeine condition 
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Figure 4: The effect of caffeine and bright light on subjective sleepiness. 
 
Values expressed as means ± SEM. The squares represent the placebo condition, triangles 
represent the caffeine condition, filled symbols represent the dim light conditions and open 
symbols represent the bright light conditions. Bright light significantly increased scores on the 
KSS as compared to the dim light conditions. * denotes a difference between bright light-placebo 
and dim light-placebo conditions.  
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who had a larger magnitude of change in DPG fell asleep faster in a nighttime sleep opportunity 
compared to those that did not have much change in this thermoregulatory parameter (Krauchi, 
Cajochen et al. 2000). We did not find a significant individual effect of caffeine on SOL in the 
current study despite the delay in peripheral heat loss in the caffeine conditions. This may 
suggest that SOL would have been longer in the caffeine condition if the experimental design 
had scheduled sleep to occur earlier than 6 hours post pill administration, (prior to the observed 
increase in the DPG). We did not find an effect for bright light on the DPG in the placebo 
condition whereas previous research findings have shown a decrease in the DPG with bright light 
exposure that occurred 2.5 hours prior to habitual sleep time (Cajochen, Munch et al. 2005). This 
discrepancy may be explained by the circadian timing of which bright light exposure occurred in 
both studies. There is a circadian increase in peripheral heat loss that occurs around the time of 
melatonin onset (Krauchi and Wirz-Justice 1994). In fact, the increase in the magnitude change 
in the DPG that occurs 90 minutes prior to habitual sleep is a good predictor for faster sleep 
onset (Krauchi, Cajochen et al. 1999). Caffeine in the current study was given at 3 hours prior to 
habitual sleep onset and attenuated the increase in DPG similar to what was observed with bright 
light (Cajochen 2005). Data from the placebo condition in the study by Cajochen et al., 
demonstrate that the circadian rise in DPG begins to taper off around the time of habitual sleep 
onset (Cajochen, Munch et al. 2005) and this is when bright light exposure began in the current 
study. It may be that caffeine maximally affected the DPG and bright light exposure was not able 
to further affect this variable at a circadian time when levels begin to taper off.  This may also 
explain why bright light alone did not affect SOL but that the interaction of caffeine and bright 
light did have a significant effect on SOL.  
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Caffeine with bright light, 6 hours prior to bedtime reduced slow wave sleep in the 
current study. Previous research findings have shown a reduction in slow wave sleep and EEG 
delta band spectral activity when caffeine (100 mg) was given at bedtime (Landolt, Dijk et al. 
1995). To our knowledge this is the first study to show that caffeine in conjunction with bright 
light affects the amount of slow wave sleep 6 hours preceding a night time sleep opportunity. 
The reduction in slow wave sleep occurred despite the increase in sleep homeostatic drive from 
the 3 hours of extended wakefulness. Previous research findings have shown that slow wave 
sleep and delta band spectral activity are markers of sleep homeostatic pressure, with increased 
time and intensity reflecting time awake from the previous sleep episode (Paterson, Nutt et al. 
2009). Further, adenosine has been shown to build up throughout the day in the basal forebrain 
of cats, and dissipate with sleep (Porkka-Heiskanen, Strecker et al. 1997). It has therefore been 
proposed that adenosine acts on adenosine A1 and A2A receptors located on the ventral lateral 
preoptic area (VLPO) of the hypothalamus and cortex to promote sleep (Saper, Scammell et al. 
2005). Results from the current study are consistent with the physiological model that caffeine 
increases arousal through its action as an adenosine receptor antagonist.   
It has been shown that nighttime caffeine (200 mg) administration can reduce 
endogenous melatonin levels in young men (Wright, Badia et al. 1997) and young women during 
the luteal phase(Wright, Myers et al. 2000). These research findings suggest that the effect of 
caffeine on core temperature and peripheral heat loss in the current study may be mediated in 
part by a reduction of melatonin levels. The result of which may be a decreased ability of 
melatonin to evoke cutaneous vasodilation and peripheral heat loss as has been shown with 
daytime exogenous melatonin administration (Krauchi, Cajochen et al. 2000; Aoki, Stephens et 
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al. 2003; Aoki, Stephens et al. 2006; Krauchi, Cajochen et al. 2006).  Future studies will need to 
examine this possibility. 
 Bright light of ~3000 lux did not significantly impact core temperature or the DPG as has 
been previously shown (Badia, Myers et al. 1991; Dijk, Cajochen et al. 1991; Wright, Badia et 
al. 1997; Burgess, Sletten et al. 2001; Cajochen, Munch et al. 2005).  This may be explained in 
part by the effect of caffeine on these variables when given 3 hours earlier.  As mentioned above, 
caffeine may have maximally affected these variables via adenosine antagonism of melatonin 
levels. It may also reflect a lack of statistical power to detect significant differences in these 
variables at this experimental time period.  
In summary, the current study findings show that in young healthy individuals caffeine 
not only impacts the thermoregulatory system around the time of habitual sleep onset by 
preventing the circadian fall in CBT but also by delaying the circadian increase in peripheral heat 
loss. Further, the combination of caffeine and bright light reduced the amount of slow wave sleep 
compared to the other conditions and significantly increased sleep onset latency. The effects of 
caffeine on thermoregulatory and sleep physiology occurred despite an increase in sleep 
homeostatic drive from the delayed bedtime. This may have implications for individuals who 
commonly consume caffeine and have diseases and/or conditions that affect the 
thermoregulatory system (i.e diabetes, vasospastic syndrome, menopause). Future studies may 
want to examine the effect of caffeine on sleep and thermoregulatory physiology in these specific 
populations. 
 
 
 
  
100 
 
References 
 
 
Aoki, K., D. P. Stephens, et al. (2003). "Cutaneous vasoconstrictor response to whole body skin 
cooling is altered by time of day." J Appl Physiol 94(3): 930-4. 
 
Aoki, K., D. P. Stephens, et al. (2006). "Modification of cutaneous vasodilator response to heat 
stress by daytime exogenous melatonin administration." Am J Physiol Regul Integr 
Comp Physiol 291(3): R619-24. 
 
Badia, P., B. Myers, et al. (1991). "Bright light effects on body temperature, alertness, EEG and 
behavior." Physiol Behav 50(3): 583-8. 
 
Barone, J. J. and H. R. Roberts (1996). "Caffeine consumption." Food Chem Toxicol 34(1): 119-
29. 
 
Burgess, H. J., T. Sletten, et al. (2001). "Effects of bright light and melatonin on sleep 
propensity, temperature, and cardiac activity at night." J Appl Physiol 91(3): 1214-22. 
 
Cajochen, C., M. Munch, et al. (2005). "High sensitivity of human melatonin, alertness, 
thermoregulation, and heart rate to short wavelength light." J Clin Endocrinol Metab 
90(3): 1311-6. 
 
Dijk, D. J., C. Cajochen, et al. (1991). "Effect of a single 3-hour exposure to bright light on core 
body temperature and sleep in humans." Neurosci Lett 121(1-2): 59-62. 
 
Dijk, D. J. and M. von Schantz (2005). "Timing and consolidation of human sleep, wakefulness, 
and performance by a symphony of oscillators." J Biol Rhythms 20(4): 279-90. 
 
Drapeau, C., I. Hamel-Hebert, et al. (2006). "Challenging sleep in aging: the effects of 200 mg of 
caffeine during the evening in young and middle-aged moderate caffeine consumers." J 
Sleep Res 15(2): 133-41. 
 
Gharib, A., D. Reynaud, et al. (1989). "Adenosine analogs elevate N-acetylserotonin and 
melatonin in rat pineal gland." Neurosci Lett 106(3): 345-9. 
 
Huang, Z. L., W. M. Qu, et al. (2005). "Adenosine A2A, but not A1, receptors mediate the 
arousal effect of caffeine." Nat Neurosci 8(7): 858-9. 
 
Krauchi, K., C. Cajochen, et al. (2006). "Thermoregulatory effects of melatonin in relation to 
sleepiness." Chronobiol Int 23(1-2): 475-84. 
 
Krauchi, K., C. Cajochen, et al. (1999). "Warm feet promote the rapid onset of sleep." Nature 
401(6748): 36-7. 
 
101 
 
Krauchi, K., C. Cajochen, et al. (2000). "Functional link between distal vasodilation and sleep-
onset latency?" Am J Physiol Regul Integr Comp Physiol 278(3): R741-8. 
 
Krauchi, K. and A. Wirz-Justice (1994). "Circadian rhythm of heat production, heart rate, and 
skin and core temperature under unmasking conditions in men." Am J Physiol 267(3 Pt 
2): R819-29. 
 
Kumar, V. M., R. Vetrivelan, et al. (2007). "Noradrenergic afferents and receptors in the medial 
preoptic area: neuroanatomical and neurochemical links between the regulation of sleep 
and body temperature." Neurochem Int 50(6): 783-90. 
 
Landolt, H. P., D. J. Dijk, et al. (1995). "Caffeine reduces low-frequency delta activity in the 
human sleep EEG." Neuropsychopharmacology 12(3): 229-38. 
 
Lewy, A. J., T. A. Wehr, et al. (1980). "Light suppresses melatonin secretion in humans." 
Science 210(4475): 1267-9. 
 
McIntyre, I. M., T. R. Norman, et al. (1989). "Human melatonin suppression by light is intensity 
dependent." J Pineal Res 6(2): 149-56. 
 
Morairty, S., D. Rainnie, et al. (2004). "Disinhibition of ventrolateral preoptic area sleep-active 
neurons by adenosine: a new mechanism for sleep promotion." Neuroscience 123(2): 
451-7. 
 
Nawrot, P., S. Jordan, et al. (2003). "Effects of caffeine on human health." Food Addit Contam 
20(1): 1-30. 
 
Okuma, T., H. Matsuoka, et al. (1982). "Model insomnia by methylphenidate and caffeine and 
use in the evaluation of temazepam." Psychopharmacology (Berl) 76(3): 201-8. 
 
Paterson, L. M., D. J. Nutt, et al. (2009). "Effects on sleep stages and microarchitecture of 
caffeine and its combination with zolpidem or trazodone in healthy volunteers." J 
Psychopharmacol 23(5): 487-94. 
 
Porkka-Heiskanen, T., R. E. Strecker, et al. (1997). "Adenosine: a mediator of the sleep-inducing 
effects of prolonged wakefulness." Science 276(5316): 1265-8. 
 
Rubinstein, E. H. and D. I. Sessler (1990). "Skin-surface temperature gradients correlate with 
fingertip blood flow in humans." Anesthesiology 73(3): 541-5. 
 
Saper, C. B., T. E. Scammell, et al. (2005). "Hypothalamic regulation of sleep and circadian 
rhythms." Nature 437(7063): 1257-63. 
 
Szymusiak, R., I. Gvilia, et al. (2007). "Hypothalamic control of sleep." Sleep Med 8(4): 291-
301. 
102 
 
Van Someren, E. J. (2000). "More than a marker: interaction between the circadian regulation of 
temperature and sleep, age-related changes, and treatment possibilities." Chronobiol Int 
17(3): 313-54. 
 
Wright, K. P., Jr., P. Badia, et al. (1997). "Caffeine and light effects on nighttime melatonin and 
temperature levels in sleep-deprived humans." Brain Res 747(1): 78-84. 
 
Wright, K. P., Jr., B. L. Myers, et al. (2000). "Acute effects of bright light and caffeine on 
nighttime melatonin and temperature levels in women taking and not taking oral 
contraceptives." Brain Res 873(2): 310-7. 
 
Zepelin, H. (2000). Mammalian sleep. Philadelphia, W.B. Saunders company  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
103 
 
 
CHAPTER 5 
 
CONCLUSION 
 
Rachel R. Markwald 
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Summary of results 
The purpose of this dissertation was to address the following deficiencies in our present 
state of knowledge about the relationship between sleep and thermoregulatory physiology.  First, 
it was unknown whether a melatonin receptor analogue ramelteon would impact daytime sleep 
and body temperature, and if there is a relationship between the two processes with this 
pharmaceutical compound. Therefore, we tested the hypothesis that ramelteon (8mg) would 
reduce CBT and increase the DPG under controlled bed rest conditions, as well as decrease SOL 
and WASO and increase TST in a daytime sleep opportunity. We also hypothesized that a 
greater change in DPG would be associated with a shorter SOL. We found that ramelteon 
significantly improved daytime sleep, lowered CBT, increased peripheral heat loss, and that the 
magnitude of increase in the DPG and distal skin temperature were correlated with a faster 
latency to sleep in the ramelteon condition.  
Secondly, it was unknown if exogenous melatonin affects metabolic rate as this would 
decrease heat production and might act as an additional thermoregulatory signal in the regulation 
of sleep/wakefulness. We tested the hypothesis that exogenous melatonin (5mg) would acutely 
decrease resting energy expenditure as assessed by volume of oxygen consumption (VO2) when 
compared to placebo during the biological daytime when endogenous melatonin levels are low 
and CBT is high. We showed that exogenous melatonin acutely lowered resting energy 
expenditure and VO2 during the late afternoon when endogenous melatonin levels are low. 
Finally, it was not known how caffeine and bright light may individually, or in a 
combined fashion, impact the sleep and thermoregulatory systems at the time of habitual sleep 
onset. Specifically, to our knowledge, no study has examined the effect of caffeine taken 6 hours 
prior to a delayed bedtime on skin temperature physiology. Thus, we tested the hypothesis that 
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caffeine would act individually and in combination with bright light to attenuate the circadian 
fall in core temperature, attenuate the circadian rise in the DPG near the habitual bedtime, as well 
as increase SOL and decrease the amount of slow wave sleep during a nighttime sleep 
opportunity. We found that caffeine administration 6 h prior to a delayed nighttime sleep 
opportunity attenuated the circadian fall in CBT, delayed the circadian increase in distal skin 
temperature measured at the foot, and the DPG, while the interaction of bright light and caffeine 
significantly reduced the percentage of slow wave sleep and significantly increased SOL as 
compared to either condition alone.  
In summary, this dissertation aimed to improve our understanding of the relationship 
between the sleep and thermoregulatory systems. We showed that a melatonin analogue 
improved daytime sleep and produced a thermoregulatory pattern similar to what is observed at 
night when endogenous melatonin levels are high. Furthermore, daytime exogenous melatonin 
decreased metabolic rate and may contribute to the circadian variation in resting energy 
expenditure with a trough occurring around the time of habitual sleep onset. Lastly, caffeine and 
bright light (two common pharmaceutical and environmental factors) negatively impacted both 
the sleep and thermoregulatory systems near bedtime.  
 
Future directions  
Possible extensions of the research from this dissertation include the following.  First, it 
has been reported that exogenous melatonin also improves daytime sleep and produces a 
thermoregulatory pattern similar to what is observed during the biological night when 
endogenous melatonin levels are high (Hughes and Badia 1997; Krauchi, Cajochen et al. 2006). 
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Exogenous melatonin however, is not currently regulated by the food and drug administration in 
the United States and may not be a safe option for the treatment of insomnia. Furthermore, the 
development of melatonin analogues (i.e. ramelteon) with longer half lives and greater binding 
specificity to the G-protein coupled melatonin MT1 and MT2 receptors may provide an 
advantage over melatonin in improving sleep. As we learn more about the discrete actions of 
these receptors, the development of even more specific analogues may be a viable treatment 
option for individuals who suffer from insomnia related to circadian sleep disorders.  
Second, although this dissertation demonstrated that daytime exogenous melatonin can 
acutely reduce resting energy expenditure; future research will need to verify these findings in 
the presence of thermoregulatory variables. The use of a within-subjects research design may be 
advantageous in detecting small but physiologically meaningful changes in these metabolic 
variables. The relationship between thermoregulatory (i.e. the DPG) and metabolic variables 
have not been examined simultaneously with acute daytime exogenous melatonin administration. 
Finally, our results show that in young healthy individuals, caffeine and bright light 
negatively impact nocturnal sleep via slow wave sleep reduction and an increase in SOL, and this 
may be due in part to caffeine-induced changes in thermoregulatory physiology. This may have 
implications for individuals who commonly consume caffeine and have diseases and/or 
conditions that affect the thermoregulatory system (i.e diabetes, vasospastic syndrome, 
menopause). Future studies may want to examine the effect of caffeine on sleep and 
thermoregulatory physiology in these specific populations. Additionally, future studies may want 
to examine the effect of caffeine on EEG spectral power throughout the sleep period to see if 
delta band activity is also reduced.  
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